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RÉSUMÉ  
 
L’hypertension pulmonaire (HP) est une maladie dont l’étiologie est inconnue et 
qui entraîne ultimement une défaillance du ventricule droit (VD) et le décès. L’HP 
peut être induite chez le rat par la la monocrotaline (MCT), un alcaloïde 
pyrrolizidique extrait de la plante Crotalaria Spectabilis, causant des lésions à 
l’endothélium des artères pulmonaires, menant à un épaississement de ces 
dernières et à une augmentation de la résistance vasculaire. Ceci à pour 
conséquence de causer une hypertrophie du VD, de l’inflammation, une 
dysfonction endothéliale NO-dépendante des artères coronariennes et une 
augmentation des peptides natriurétiques circulants.  
Objectif: Nous avons testé l’hypothèse selon laquelle l’étiopathologie de l’HP 
impliquerait le récepteur à ocytocine (OTR) dû à son implication fonctionnelle 
avec les cytokines inflammatoires et la libération du peptide natriurétique atrial 
(ANP) et du NO. 
Méthodes: Des rats mâles Sprague-Dawley pesant 220-250g reçurent une seule 
injection sous-cutanée de MCT (60 mg/kg). 6 à 7 semaines (46±1 jours) suivant 
l’injection, les rats furent sacrifiés et l’expression génique et protéique fut 
déterminée par PCR en temps réel et par western blot, respectivement, dans le 
VD et le ventricule gauche  (VG)  
Résultats: Les rats traités au MCT démontrèrent une augmentation significative  
du VD. Une hypertrophie du VD était évidente puisque le ratio du VD sur le VG 
ainsi que le poids du septum étaient près de 77% plus élevés chez les rats traités 
au MCT que chez les rats contrôles. Le traitement au MCT augmenta 
l’expression génique d’ANP (3.7-fois dans le VG et 8-fois dans le VD) ainisi que 
le NP du cerveau (2.7-fois dans le VG et 10-fois dans le VD). Les transcrits de 
trois récepteurs de NP augmentèrent significativement (0.3-2 fois) seulement 
dans le VD. L’expression protéique de la NO synthase (iNOS) fut également 
augmentée de façon sélective dans le VD. Par contre, les transcripts de NOS 
endothéliale et de NOS neuronale étaient plus élevés (0.5-2 fold) dans le VG. 
L’ARNm et l’expression protéique d’OTR furent diminués de 50% dans le VD, 
tandis qu’une augmentation de l’expression des cytokines IL-1β and IL-6 fut 
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observée. L’ARNm de Nab1, un marqueur d’hypertrophie pathologique, fut 
augmentée de deux-fois dans le VD. 
Conclusion: L’augmentation d’expression génique de NP dans le VD des rats 
traités au MCT est associée à une augmentation des transcripts du récepteur 
NP, suggérant une action locale de NP dans le VD durant l’HP. L’expression 
d’OTR est atténuée dans le VD, possiblement par des cytokines inflammatoires 
puisque le promoteur du gène de l’OTR contient de multiples éléments de 
réponse aux interleukines. Diminuer l’expression d’OTR dans le VD durant 
l’hypertension pulmonaire pourrait influencer de manière positive la fonction 
cardiaque car l’OTR régule la contractilité et le rythme cardiaque. 
 
Mots clés: hypertension pulmonaire, hypertrophie du ventricule droit 
monocrotaline, récepteur à ocytocine, inflammation, peptides natriurétiques.      
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SUMMARY 
 
Pulmonary hypertension (PH) is a disease of unknown etiology that ultimately 
causes failure of right ventricle (RV) with a lethal outcome. PH can be induced in 
the rat with monocrotaline (MCT), a pyrrolizidine alkaloid from the plant Crotolaria 
spectabilis that damages the pulmonary artery endothelium leading to thickening 
of the pulmonary arteries and increased vascular resistance. This subsequently 
results in RV hypertrophy, inflammation, nitric oxide (NO)-associated coronary 
endothelial dysfunction and increment of natriuretic peptides (NP) in the 
circulation.  
Objective: We verified hypothesis that the etiopathogenesis of PH involves the 
oxytocin receptor (OTR) because of its functional association with inflammatory 
cytokines and release of atrial natriuretic peptide (ANP) and NO. 
Methods: Male Sprague-Dawley rats weighing 220-250g received a single 
subcutaneous injection of 60 mg/kg of MCT. Six to 7 weeks (46±1 days) following 
the injection, rats were sacrificed and gene and protein expression were detected 
by real-time PCR and western-blot analysis, respectively, in the RV and LV (left 
ventricle). 
Results: MCT-treated rats displayed significant increases in RV weight. RV 
hypertrophy was evident as the ratio of the RV to LV plus septum weight was 
nearly 77% higher in MCT-treated rats compared to control rats. MCT treatment 
increased transcripts of ANP (3.7-fold in the LV and 8-fold in RV) and brain NP 
(2.7-fold in the LV and 10-fold in RV). Transcripts for three NP receptors 
significantly increased (0.3-2 fold) only in the RV. iNOS (inducible NO synthase) 
protein expression also increased selectively in the RV. In contrast, the 
endothelial NOS and neural NOS transcripts heightened (0.5-2 fold) in the LV. 
Both OTR mRNA and protein were decreased by 50% in the RV, whereas an up-
regulation of cytokines IL-1β and IL-6 was observed. Nab1 mRNA, a marker of 
pathological hypertrophy, increased two-fold in the RV. 
Conclusion: Increased gene expression of NP in the RV of the MCT-treated rat 
correlates with upregulation of NP receptor transcripts indicating local NP action 
in the RV during PH. OTR expression is decreased in the RV possibly by 
inflammatory cytokines, IL-1β and IL-6 because OTR promoter region contains 
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multiple putative interleukin-response elements. Lowering OTR in RV during 
pulmonary hypertension can influence cardiac function since OT regulates heart 
rate and cardiac contractility and is linked with cardioprotective system ANP and 
NO.  
 
Keywords: pulmonary hypertension, right ventricular hypertrophy, monocrotaline, 
oxytocin receptor, inflammation, natriuretic peptides.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7
CONTENTS 
Summary………………………………………………………………………......3 
List of figures……………………………………………………………………..13 
List of tables………………………………………………………………….…..14 
List of abbreviations……………………………………………………………..15 
Acknowledgements………………………………………………………….......19 
Dedication ………………………………………………………………………..20 
Ι. Introduction…………………………………………………………………….21 
Ι.Ι. Myocardial hypertrophy…………………………………………………..…21 
       Ι.Ι.1. General…………………………………………………………….….21 
      Ι.Ι.2.  Pathogenesis………………………………………………………...22 
            Ι.Ι.2.1. Role of genetic factors……………………………………..…23               
            Ι.Ι.2.2. Role of oxidative stress……………………………………....23  
            Ι.Ι.2.3. Role of inflammation………………………………………….24 
              Ι.Ι.2.4. Role of energy metabolism…………………………………..26 
       Ι.Ι.3. Molecular mechanisms involved in cardiac hypertrophy.…………27 
            Ι.Ι.3.1. Vasoactive peptides…………………………………………....27    
                       Ι.Ι.3.1.1 ANP and BNP as markers of cardiac hypertrophy...27  
                      Ι.Ι.3.1.2 Cardioprotective role of GC-A, GC-B,  
                                      and NPR-C in the hypertrophic heart……………….29 
                       
 8
                      Ι.Ι.3.1.3 Role of other vasoactive peptides in  
                                     cardiac hypertrophy……………………………………30 
            Ι.Ι.3.2. Peptide growth factors…………………………………………30  
              Ι.Ι.3.3. Hormones……………………………………………………….32  
      Ι.Ι.4. Molecular pathways…………………………………………………….32 
    Ι.Ι.4.1. PI3K/Akt pathway………………………………………………33 
   Ι.Ι.4.2. MAPKs pathway………………………………………………..33 
   Ι.Ι.4.3. PKC pathway…………………………………………………...34 
   Ι.Ι.4.4. NF-κB pathway…………………………………………………34 
      Ι.Ι.5. Apoptosis……………………………………………………………….35 
  Ι.ΙΙ. Pulmonary hypertension and right ventricular hypertrophy…………….36 
     Ι.ΙΙ.1. Modulation of cardiac makers in this pathology………….…………36  
     Ι.ΙΙ.2. Investigations of right and left ventricular function following  
                 induction of pulmonary hypertension with the monocrotaline…….37  
   Ι.ΙΙΙ. Oxytocin (OT) and Oxytocin receptor (OTR) in the heart……….…....38 
     Ι.ΙΙΙ.1. General features of OT and OTR……………………………………38  
              Ι.ΙΙΙ.1.1. Cardiovascular functions of OT……………..………….….39 
                Ι.ΙΙΙ.1.2. OT-ANP interaction in central nervous system……….….41 
II. Hypothesis and specific aims……………………………………………….…42 
    ΙΙ.1. Hypothesis………………………………………………………………….42 
 9
    ΙΙ.2. Specific aims..…………………………………………………………….42 
          ΙΙ.2.1. Aim #1……..…………………………………………………….….42 
          ΙΙ.2.2. Aim #2………………….…………………………………………...42 
          ΙΙ.2.3. Aim #3………………….……………………………………….…..42 
III. Experimental design…………………………………………………………..43 
IV. Material and methods…………………………………………………………44 
      IV.1 Animal treatment and collection of specimens……………………….44  
      IV.2. Measurement of gene expression…………………………………….44 
           IV. 2.1. Table 1. Materials for Real-time PCR………………………….44  
           IV.2.2. Preparation of total RNA and quantification of RNA  
                        Concentration……………………………………………………...45 
                      ΙV.2.2.1. Preparation of total RNA……………………………....45 
                      ΙV.2.2.2. Determination of RNA concentration…………….…..45 
           IV.2.3. Reverse transcription of mRNA to cDNA………………………46 
           IV.2.4. Sequences of the primers used for PCR amplification of 
                         cDNA samples…………………………………………......……46 
           IV.2.5. Programs for amplification of gene sequences by  
                        Real-time PCR and control of amplification conditions……. 48 
           IV.2.6 Selection of housekeeping gene for measurement of gene  
                       expression semi quantitatively…………………………………48  
           IV.2.7 Methodology used for calculation of the gene expression 
 10
                     on the basis results provided by Real-time cycler…….………49 
           IV.2.8 Statistical evaluation of the results obtained by Real-time    
                        PCR………………………………………………………………50 
      IV.3. Cardiac protein extraction and Western blotting…………………..50 
           IV.3.1. Processing of cardiac samples and measurement of  
                          protein concentration………………………………………....50 
                      ΙV.3.1.1. Processing of cardiac samples…………………….50 
                      ΙV.3.1.2. Measurement of protein concentration…………....50 
            IV.3.2. Table 2. Reagents  for Western-blot…………………………51   
            IV.3.3. Electrophoresis conditions, electro-transfer proteins  
                         to the nylon membrane………………………………………..52 
            IV.3.4. Membrane processing, incubations time, reaction with  
                         specific primary antibodies, washing conditions,  
                         incubation with secondary antibodies………………………..52 
           IV.3.5. Development of Western blotting reaction by  
                        chemiluminescence method……………………………….…..53 
           IV.3.6. Molecular weight of the bands obtained for the studied  
                        protein of interest and expected molecular size as 
                       recommended by antibody provider and published in  
                       the literature……………………………………………………...54 
           IV.3.7. Quantification of the bands intensity using computer  
                        Software………………………………………………………….54 
           IV.3.8. Methodology used for calculation of protein  
                        expression in Western-blot……………………………………..55 
           IV.3.9. Statistical evaluation of the results obtained by  
                        Western blotting…………………………………………………..55 
V. Results…………………………………………………………………………..56 
 11
    V.1. Effect of MCT treatment on body weights and weights  
             of selected organs………………………………………………………..56  
     V.2. Effect of MCT treatment on NPs gene expressions in  
            the right and the left ventricles……………………………………..……57  
   V.3. Effect of MCT treatment on NP receptors gene  
            expressions in the right and the left ventricles…………………………57  
V.4. Effect of MCT treatment on NOS gene and protein  
       expressions in the right and the left ventricles…………………………58  
V.5. Effect of MCT treatment on OTR gene and  
       protein expressions in the right and the left ventricles…………….….59  
V.6. Effect of MCT treatment on expressions of  
       proinflammatory cytokines in the right and the left ventricles………..60  
V.7. Effect of MCT treatment on a marker of pathological 
       hypertrophy gene and protein expressions  
        in the right and the left ventricles………………………………….……60  
V.8. Effect of MCT treatment on ventricular expression of  
       factors involved in metabolic functions………………………………...61 
VΙ. Discussion……………………………………………………………………70 
    VΙ.1.  Rat model of RV hypertrophy…………………………………………70 
    VΙ.2.  Possible role of inflammatory cytokines  
               in the regulation of OTR…………………………………….…………72 
    VΙ.3.  Involvement of NO in RV hypertrophy………………………………..74 
 12
     VΙ.4.  Role of Natriuretic Peptides…………………………………………...75 
     VΙ.5.  Role of OT-Associated Metabolic Factors…………………………..77 
VII. Conclusions and perspectives……………………………………………...79 
     VII.1. Conclusions…………………………………….………………………79 
     VII.2. Perspectives……………………………………………………………79 
              VII.2.1. OTR and inflammation………………………………………..79  
              VII.2.2. OTR and metabolism …………………………………………80 
VIII. References……………………………………………………………………82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13
LIST OF FIGURES 
 
Results:  
           Figure 1. Effect of MCT treatment on NPs gene expressions in  
                           the right and the left ventricles………………..…………….63  
           Figure 2. Effect of MCT treatment on NP receptors gene  
                          expressions in the right and the left ventricles……………..64  
           Figure 3. Effect of MCT treatment on NOS gene and protein  
                      expressions in the right and the left ventricles……………..65 
      Figure 4. Effect of MCT treatment on OTR gene and  
                     protein expressions in the right and the left ventricles……..66  
      Figure 5. Effect of MCT treatment on expressions of  
                     proinflammatory cytokines in the right and the  
                     left ventricles……………………………………………………67 
      Figure 6. Effect of MCT treatment on a marker of pathological 
                     hypertrophy gene and protein expressions  
                     in the right and the left ventricles…………………………….68 
      Figure 7. Effect of MCT treatment on ventricular expression of  
                          factors involved in metabolic functions……………………..69 
 
 
 
 
 
 14
LIST OF TABLES 
 
Material and methods: 
 Table 1. Materials for Real-time PCR………………………………….44 
 Table 2. Reagents for Western-blot……………………………………51   
           Table 3. Primary and secondary antibodies used in Westen-Blot….53 
           Table 4. The size of Protein Bands……………………………………54 
 
Results: 
           Table 1. The effect of monocrotaline treatment on selected organ  
    weights…………………………………………………………..62 
Table 2. The effect of monocrotaline treatment on heart weights……62 
 
  
 
 
 
 
 
 
 
 
 
 
 
 15
LIST OF ABBREVIATIONS 
AIF  : apoptosis-inducing factor 
ANF  : atrial natriuretic factor 
Ang II  : angiotensin II 
Akt  : protein kinase B 
ANP  : atrial natriuretic peptides 
AP-1  : activator protein 1 
ATP  : adenosine triphosphate 
AT-1  : angiotensin II type 1 receptor 
Bcl2  : B-cell CLL/lymphoma 2 
BH4  : tetrahydrobiopterin 
BNP  : brain natriuretic peptides 
BSA  : bovine serum albumin 
CNP  : C-type natriuretic peptide 
CT-1  : cardiotrophin-1  
CT  : threshold cycle 
Cyt c  : cytochrome c 
DEPC  : diethylpyrocarbonate 
DNA  : deoxyribonucleic acid 
dNTP  : deoxyribonucleotide triphosphate 
DTT  : dithiothreitol 
EDTA  : ethylenediaminetetraacetic acid 
eNOS  : endothelial nitric oxide synthase 
erg  : early growth reponse 
ET-1  : endothelin-1  
 16
FGF-2  : fibroblast growth factors-2  
FLICE : fas-associated death domain-like interleukin-1 -converting   
                      enzyme 
GAPDH : glyceraldehyde-3-phosphate dehydrogenase 
GC-A  : guanylyl cyclase A  
GC-A-/- : GC-A knockout 
GC-B  : guanylyl cyclase B 
GH  : growth hormone 
cGMP  : cyclic guanosine monophosphate  
HCM  : hypertrophic cardiomyopathy 
H2O2  : hydrogen peroxide 
HPRT  : hypoxanthine guanine phosphoribosyl transferase  
IGF-1  : insulin-like growth factor-1 
JNK  : c-Jun N-terminal kinase 
iNOS  : inducible nitric oxide synthase   
IRAP  : insulin regulated aminopeptidase  
IL-1β  : interteukin-1 β 
IL-6  : interleukin-6 
LIF  : leukaemia-inhibitory factor  
LV  : left ventricle 
MAPK  : mitogen-activated protein kinase  
MCT  : monocrotaline 
MMP  : matrix metalloproteinase 
mRNA : messanger RNA 
Nab1   : NGF1A-binding protein 
 17
NF-κB  : nuclear factor kappa-light-chain-enhancer of activated B cells 
nNOS  : neuronal nitric nxide synthase 
NO  : nitric oxide 
NOS  : nitric oxide synthases  
NP  : natriuretic peptides  
NPR-A : natriuretic peptide receptor A  
NF-IL6 : nuclear factor IL-6 
NT-proBNP : N-terminal proBNP 
OD  : optical density 
OT  : oxytocin  
OTR  : oxytocin receptor 
PCR  : polymerase chain reaction 
PE  : phenylephrine 
PH  : Pulmonary hypertension 
PI-3/Akt : phosphatidylinositol 3-kinase/Akt 
PKB  : protein kinase B 
PKC  : protein kinase C 
PMSF  : phenylmethanesulphonylfluoride 
RIPA  : radio immunoprecipitation assay 
RNA  : ribonucleic acid 
rRNA  : ribosomal RNA  
ROS  : reactive oxygen species 
RT  : room temperature 
RV  : right ventricle 
RVH  : right ventricle hypertrophy 
 18
SDHA  : succinate dehydrogenase complex, subunit A 
SDS  : sodium dodecyl sulfate 
TBS  : Tris Buffered Saline 
TEMED : tetramethylethylenediamine 
TNFα  : tumor necrosis factor α 
TGF-β1 : transforming growth factor β-1 
UBC  : ubiquitin C  
UV  : ultraviolet 
 
YWHAQ : tyrosine 3-monooxygenase/tryptophan 5-monooxygenase    
    
                       activation protein, theta polypeptide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 19
 
ACKNOWLEDGEMENTS 
 
First and foremost, I would like to express my most sincere appreciation to 
my supervisors Dr. Marek Jankowski and Dr. Jolanta Gutkowska, for their solid 
and skillful guidance, as well as their encouragement throughout this dissertation.  
Furthermore, I acknowledge Dr. Tom Broderick for kindly providing us 
experimental samples and my colleague, Dr. Donghao Wang, enthusiastic 
supporter of my efforts.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20
 
DEDICATION 
 
I dedicate my work to my loving and caring wife and my lovely daughter 
and son, whose love and strength have sustained my energy to complete this 
work.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 21
Ι. INTRODUCTION 
Ι.Ι. Myocardial hypertrophy 
Ι.Ι.1. General 
Myocardial hypertrophy and its subsequent heart failure are one of the leading 
causes of morbidity and mortality in Western world. This disease is characterized 
in an increase in heart muscle mass, which reflects a remodeling of the 
myocardium in response to mechanical stress and various stimuli. Cardiac 
hypertrophy is classified into two types: physiological and pathological 
hypertrophies. Physiological hypertrophy is reversible, not associated with 
cardiac damage, and occurs in healthy individuals following exercise and in 
pregnancy. In contrast, pathological hypertrophy is caused by the ventricle 
adapting to increased stress, such as chronically increased volume load or 
increased pressure load. Hypertrophy can also result from disease of the heart 
(valve disease, cardiomyopathies), genetic abnormalities (e.g., hypertrophic 
cardiomyopathy), and as a consequence of coronary artery disease. Sustained 
pathological hypertrophy can eventually result in a decline in left and right 
ventricular sizes and functions, which lead to heart failure. The major causes of 
pathological hypertrophy are hypertension, genetic polymorphisms, and loss of 
myocytes following ischemic damage. Altered cardiac metabolism can also be an 
important component leading to hypertrophy [Rajabi et al. 2007].  
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Ι.Ι.2.  Pathogenesis  
Many factors have been implicated in cardiac remodeling including alterations in 
gene expression in myocytes, cardiomyocytes apoptosis, cytokines, and growth 
factors. These factors influence cardiac dynamics and deficits in energy 
metabolism as well as alterations in cardiac extracellular matrix composition. 
Cardiac hypertrophy develops in two ways. The first one is a concentric 
hypertrophy caused by chronic pressure overload leading to reduced left 
ventricular volume and increased wall thickness. The second one is the eccentric 
hypertrophy due to volume overload and causing dilation and thinning of the 
heart wall. The mechanism of eccentric expansion is induced by the addition of 
the contractile sarcomere in series, which causes cell elongation. In contrast, the 
mechanism of concentric enlargement is caused by addition of sarcomeres in 
parallel, which results in increased cell thickness [Barry et al 2008]. The primary 
molecular cause of enlargement of the heart is hypertrophy of myocytes without 
an increase in the cell number. The increase in myocyte size accompanies an 
increase in the number of cardiac fibroblasts releasing fibrotic deposits and 
increased myocardial stiffness [Wakatsuki et al. 2004]. This in turn leads to 
overload and promotes further hypertrophy and cell death, resulting in a 
detrimental cycles of cardiac enlargement and myocyte loss. In experimental 
animal model, monocrotaline (MCT), a toxic pyrrolizidine alkaloid of plant origin 
has been used extensively to produce pulmonary hypertension (PH) in rats 
[Schultze et al 1998]. MCT can selectively injure the vascular endothelium of the 
lung and induces pulmonary vasculitis. As a result develops muscularization and 
hypertrophy of media in pulmonary arteries thus increasing vascular resistance 
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and stimulating local hypertension. Then, the PH leads to compensated right 
ventricle hypertrophy (RVH), which can progress to failure within weeks 
depending on the dose of MCT and the age of the animals. 
 
Ι.Ι.2.1. Role of genetic factors 
Genetic factors are important determinants of phenotypic expression of cardiac 
hypertrophy, both in single- or in complex-gene disorders. Hypertrophic 
cardiomyopathy (HCM) defined clinically by left ventricular hypertrophy is the 
most common inherited cardiac disorder and this condition is the major cause of 
sudden death in the young under 35 years and in athletes [Keren et al. 2008]. 
HCM is usually inherited as an autosomal dominant mutation in genes that 
encode protein constituents of the sarcomere.  
              
Ι.Ι.2.2. Role of oxidative stress  
Oxidative stress is characterized by the excessive formation of reactive oxygen 
species (ROS) from the respiratory chain that cannot be adequately countered by 
intrinsic antioxidant systems. There are two sources of free radicals [Gupta et al. 
2007]. One is oxidative phosphorylation of mitochondria-generated oxygen 
radicals, such as superoxide radicals, H2O2, and hydroxyl radicals. Another 
source is lipid oxidation. It has been shown that excessive ROS generation 
triggers cell dysfunction, lipid peroxidation, and DNA mutagenesis and can lead to 
irreversible cell damage or death [Murdoch et al 2006, Sawyer et al 2002, 
Giordano et al 2005]. In the myocardium, oxygen radicals have been shown to 
alter Na+/Ca2+ exchange, Na+-K+ ATPase, and Ca2+ ATPase activities. Mutant 
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mice that lack manganese superoxide dismutase (a scavenging enzyme) show a 
severe reduction in complex II of the respiratory chain and rapidly develop dilated 
cardiomyopathy [Li et al 1995]. The involvement of eNOS and eNOS uncoupling 
in cardiac hypertrophy has been documented. The essential cofactor 
tetrahydrobiopterin (BH4) has been shown to be a key factor in eNOS catalysis. 
eNOS coupled with BH4 generates NO and L-citrulline. When BH4 availability is 
limiting, eNOS no longer produces NO but instead generates superoxide [Wever 
et al 1997; Alp et al 2004]. Studies have demonstrated that the normal (coupled) 
eNOS pathway inhibits hypertrophy and hypertrophic signaling, matrix 
metalloproteinase (MMP) activation, and cardiac dysfunction. In the presence of 
oxidant stress, depletion of substrate (arginine) and cofactors (BH4), NOS can 
become uncoupled and generate more ROS. This enhanced ROS diverts 
(forming peroxynitrite) and stimulates pathological cardiac hypertrophy and 
remodeling [Takimoto et al 2007].   
 
Ι.Ι.2.3. Role of inflammation 
Cytokines are soluble peptides that mediate cell-to-cell interactions via specific 
cell surface receptors and regulate the activation, differentiation, growth, death or 
acquisition of effector functions of immune cells. Most cytokines act as local 
autocrine or paracrine mediators and do not act in endocrine fashion. Therefore, 
systemic elevation of cytokines produces a series of local pathologic reactions. 
Accumulating evidence indicates that inflammatory cytokines play a pathogenic 
role in cardiac diseases by influencing heart contractility, inducing hypertrophy 
and promoting apoptosis or fibrosis. In the pressure overloaded ventricle, the 
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myocardium first develops adaptive hypertrophy. In the later stage this pattern of 
hypertrophy underwent a transition to chronic heart failure. Cytokines appear to 
play a significant role in this process by accelerating myocyte growth and down-
regulating cardiac function [Sasayama et al. 1999]. It has been found that, in the 
patients, sustained increases in inflammatory cytokines, such as TNF , IL-1 and 
IL-6, are the major pathogenic factors involved in cardiac remodeling and in the 
progression of chronic heart failure [Deswal et al 2001, Mann 2002, Malave et al 
2003]. Animal studies have indicated that inflammatory cytokines induce cardiac 
hypertrophy [Li et al 2000], inhibit heart contractility [Yu et al 2003], and promote 
cardiomyocyte apoptosis [Nian et al 2004]. The main hypertrophic cytokines are 
the members of the IL-6 family including IL-6 itself, leukaemia-inhibitory factor 
(LIF) and cardiotrophin-1 (CT-1). Study demonstrated that transgenic mice 
overexpressing IL-6 and IL-6 receptor developed hypertrophy of ventricular 
myocardium [Hirota et al 1995]. In another model of cardiac hypertrophy due to 
pressure overload in rats, IL-6 was significantly increased [Pan et al 1998]. CT-1 
was shown to promote cardiac myocyte survival and induce an eccentric form of 
hypertrophy both in vitro and in vivo [Jin et al 1996, Sheng et al 1996, Wollert et 
al 1996]. BNP is one of the most widely used marker of heart failure. Study has 
recently determined that combining CT-1 and BNP measurements may be a 
greater predictor of mortality in patients suffering from congestive heart failure 
than either marker alone [Tsutamoto et al 2007]. Study has indicated that IL-1β 
induces unique cardiac hypertrophy and the marked secretion of ANP and BNP 
[Harada et al 1999].  In this study, they examined the effects of IL-1β on the 
morphological changes of myocyte (MC) in comparison with the effects 
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of ET-1. They found that IL-1β induced the star-shaped MC hypertrophy 
characterized by elongation and pointed edges, while ET-1 induced the MC 
hypertrophy characterized by shapes of squares, triangles or circles. Therefore, 
they concluded that IL-1β induces unique form of cardiac hypertrophy.   
 
Ι.Ι.2.4. Role of energy metabolism 
Circulating fatty acids, glucose, lactate, amino acids, and ketone bodies as well 
as intracellular glycogen and triglycerides can be used by the heart to produce 
energy [Lehman et al 2002, Saddik et al 1991, Needly et al 1974]. Rates of 
glycolysis are accelerated in heart hypertrophy induced by pathological stimuli. In 
contrast, long-chain fatty acid oxidation is reduced in pathologically hypertrophied 
hearts [Bowles et al 1992, El Alaoui-Talibi et al 1997, Allard et al 1994]. Evidence 
from experimental and clinical studies suggest that the catabolic fate of glucose 
is an important determinant of post-ischemic myocardial function [Depre et al 
1998, Taegtmeyer et al 2000]. Dichloroacetate [Wambolt et al 2000], an activator 
of pyruvate dehydrogenase and trimetazidine, an anti-ischemic drug [Lopaschuk 
et al 2002] are two agents that modulate energy metabolism. In the ischemic 
heart these two agents have been shown to normalize cardiac function by 
stimulation of glucose oxidation and reduction of glycolysis. In addition to 
enlargement of cardiac myocytes, the hypertrophic response to pathological and 
physiological stimuli is accompanied by qualitative changes within the cardiac 
myocytes. Energy metabolism is one aspect of cardiac myocyte biology that is 
well recognized as being altered during the heart hypertrophy [Richey et al 1998, 
Bowles et al 1992, El Alaoui-Talibi et al 1997, Allard et al 1994]. Of importance is 
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the fact that changes in energy metabolism are recognized as key determinants 
in both adaptive and maladaptive cardiac hypertrophy.  
 
Ι.Ι.3. Molecular mechanisms involved in cardiac hypertrophy 
Ι.Ι.3.1. Vasoactive peptides 
Ι.Ι.3.1.1 ANP and BNP as markers of cardiac hypertrophy 
Cardiac natriuretic peptides contribute importantly to the maintenance of sodium 
and volume homeostasis in health and disease. ANP was originally identified in 
atrial myocardial extracts as a substance promoting natriuresis [de Bold et al 
1981]. It is principally produced in the atria of normal adults, but is also 
accumulated in the ventricles during development [Cameron et al 1996, 
Mercadier et al 1989] and in hypertrophied ventricles [Gu et al 1989]. BNP was 
first purified from porcine brain [Porter et al 1989]. Although expressed in brain, 
BNP is most abundant in the cardiac ventricles, where its expression is induced 
in decompensated heart failure [Langenickel et al 2000]. CNP was discovered in 
the central nervous system, although later studies indicated that expression of 
CNP in the endothelium [Suga et al 1992], macrophages [Ishizaka et al 1992], 
and cardiac fibroblasts [Horio et al 2003] is higher than that in the brain. As 
shown in figure 1, three natriuretic peptides bind to 3 natriuretic peptide 
receptors. Calderone et al [1998] investigated the effect of exogenously 
administered ANP on the cardiac cell hypertrophy induced by norepinephrine. 
They reported that ANP inhibited the cardiac myocyte enlargement, stimulated by 
norepinephrine, by mechanism involving cGMP-and Ca2+ influx. This finding 
demonstrated that endogenous ANP suppress the development of cardiac 
 28
myocyte hypertrophy. Furthermore, Horio et al [2000] have shown that inhibition 
of natriuretic peptide receptors by HS-142-1, antagonist increased the size of 
cardiac myocytes. The same research group [Horio et al 2000] has found that 
zaprinast, a specific cGMP phosphodiesterase inhibitor, suppressed the basal 
and phenylephrine (PE)-stimulated protein syntheses. These observations 
indicate that endogenous ANP inhibits cardiac myocyte hypertrophy under basal 
as well as phenylephrine-stimulated conditions, probably through a cGMP-
dependent process. Thus, ANP may play a role as autocrine factor in the 
regulation of cardiac myocyte growth. BNP exerts many similar actions as ANP 
on target organs. Accordingly, the BNP is viewed as a cardiomyocyte-derived 
antifibrotic factor and plays a role in ventricular remodeling [Tamura et al 2000]. 
Prolonged cardiac hypertrophy and heart failure are characterized by the 
increase in the expression of the ANP and BNP [Chien et al 1991]. Previous 
studies implicated the expression of ANP and BNP genes as markers for 
ventricular dysfunction [Yoshimura et al 1993]. Clarkson et al [1996] investigated 
therapeutic effects of BNP administration in six patients with isolated diastolic 
heart failure with moderately severe exertional symptoms (exercise intolerance), 
five of whom had hypertension and four of whom had LV hypertrophy. Overall, 
their findings suggest that ANP, BNP/NPR-A/cGMP system plays an important 
role in counteracting of cardiac hypertrophy.  
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Ι.Ι.3.1.2 Cardioprotective role of GC-A, GC-B, and NPR-C in the 
hypertrophic heart 
The biological actions of natriuretic peptides are mediated by specific guanylyl 
cyclase receptors (GC-A, also called natriuretic peptide receptor (NPR)-A and 
GC-B) through generation of cGMP [Hamet et al 1984, Chinkers et al 1989, Lowe 
et al 1989]. The ligand selectivity of GC-A is ANP≥ BNP>CNP [Suga et al 1992]. 
The preferred ligand for the GC-B receptor is CNP whereas ANP and BNP are 
bound with relatively less affinity [Samson 2000]. A third receptor, namely NPR-C 
does not show any ligand selectivity and thus may promote clearance of the 
peptides from the circulation. GC-A mediates the endocrine effects of ANP and 
BNP on regulating arterial blood pressure and volume homeostasis, and also the 
local antihypertrophic actions in the heart. It has paracrine function in 
vasodilatation and endochondral ossification. The important cardiovascular role 
of the ANP/GC-A system has been emphasized in gene knockout mouse models. 
For example, NPR-A deficiency in mice leads to marked cardiac hypertrophy 
[Oliver et al 1997], suggesting that the endogenous ANP-NPR-A system may 
have a  role in the regulation of cardiac cell growth. Targeted deletion of the 
peptide (ANP-/-) or its receptor (GC-A-/-), leads to severe, chronic arterial 
hypertension, cardiac hypertrophy, and sudden death [Kuhn et al 2002]. Holtwick 
et al [2003] studied  mice with conditional, selective deletion of GC-A in 
cardiomyocytes (GC-A-/-) and demonstrated that the ANP/GC-A system play an 
autocrine/paracrine roles in the heart, which include cardiomyocyte growth 
inhibition and the stimulation of diastolic relaxation.  
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Ι.Ι.3.1.3 Role of other vasoactive peptides in cardiac hypertrophy 
Vasoactive peptides such as endothelin-1 (ET-1) and angiotensin II (Ang II) have 
been reported to induce cardiac hypertrophy. ET-1 activates several intracellular 
signaling pathways in cardiac myocytes, notably the protein kinase C (PKC) 
pathway, the mitogen-activated protein kinase (MAPK) cascades, and 
phosphatidylinositol 3-kinase/Akt (PI-3/Akt) pathway [Ito et al 1993]. It is likely 
that activation of these pathways contributes to the hypertrophic response. Ang II 
causes cardiomyocyte hypertrophy and cardiac fibroblast proliferation 
concomitant with deposition of extracellular matrix, both actions being mediated 
by the Ang II type 1 (AT-1) receptors [Sadoshima et al 1993]. Ang II has also 
been reported to stimulate autocrine/paracrine release of other growth factors 
such as platelet-derived growth factor, transforming growth factor β-1 (TGF-β1), 
insulin-like growth factor-1 (IGF-1), and ET-1 in various cell types [Gibbons et al 
1992, Delafontaine et al 1993, Ito et al 1993] These growth factors may, in part, 
indirectly mediate the physiological effects of Ang II as well. Interestingly, the 
receptor for Ang IV known as insulin regulated aminopeptidase (IRAP), 
functioning as oxytocinase, has pleotropic actions and plays a role in degradation 
of oxytocin, arginine-vasopressin and other peptide hormones. 
 
Ι.Ι.3.2. Peptide growth factors 
TGF-β1 has activities important for the regulation of development, cell 
differentiation, tissue maintenance, and repair in a variety of cells and tissues 
[Massague et al 1990, Brand et al 1995]. TGF-β1 is upregulated in myocardium 
by increased work load and stimulates the hypertrophic program of cardiac gene 
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expression [Parker et al 1990]. As mentioned before, it has been reported that 
TGF- β1 is an important mediator of cardiac hypertrophy stimulated by Ang II 
[Schultz Jel et al 2002]. Fibroblast growth factor-2 (FGF-2) is also naturally 
produced by cardiac myocytes and non-myocytes in the heart, where it plays an 
autocrine and paracrine roles in cardiomyocyte hypertrophy [Takahashi et al 
1994]. IGF-1, a 70 amino-acid basic peptide, is an essential growth factor for 
somatic-cell proliferation and differentiation, and during development mediates 
biological effects of growth hormone (GH) [Rinderknecht et al 1986, Sacca et al 
1994]. IGF-1 has been shown to activate several pathways of the hypertrophic 
response, where it enhances the expression of contractile proteins such as actin, 
myosin and troponin. Rats undergoing left ventricular hypertrophy have increased 
IGF-1 mRNA and protein levels [Wahlander et al 1992, Donahuc et al 1994]. The 
signal is transduced by intracellular events. IGF-1 is one of the most potent 
natural activators of the protective AKT signaling pathway, a stimulator of cell 
growth and a potent inhibitor of programmed cell death. Therefore, IGF-1-
dependent signaling pathways may be important in the initiation of beneficial 
cardiac hypertrophy in vivo, possibly via autocrine or paracrine effects. Several 
clinical trials tested IGF-1 for a variety of indications, including growth failure, 
type 1 diabetes, type 2 diabetes. Epidemiological observations suggested that 
high IGF-I plasma levels are associated with decreased risks for heart failure. 
[Vasan et al 2003].  
  
 
 
 32
Ι.Ι.3.3. Hormones  
Thyroid hormone is generally considered as classic hormonal mediator of cardiac 
hypertrophy. Excess of thyroid hormone in experimental small animals and 
primates increases heart weight [Khoury et al 1996]. GH, the major stimulus for 
IGF-1 production and release, induces cardiac enlargement in experimental 
animals [Lei et al 1988]. Animal studies also indicate an anti-hypertrophic action 
of estrogen in the heart. In ovariectomized mice, estrogen supplementation 
activates ANP-mediated mechanism causing a 30% reduction of pressure 
overload and reduction cardiac hypertrophy [van Eickels et al 2001]. Estrogen 
prevents development of cardiac hypertrophy through the inhibition of molecules 
important in hypertrophic pathways such as calcium-sensitive protein 
phosphatase, calcineurin, Ang II or ET-1. 
 
Ι.Ι.4. Molecular pathways   
In response to hemodynamic overload, several parallel and interconnected 
intracellular signal transduction cascades are activated and mediate biological 
effects including cardiac hypertrophy [Chien et al 1993]. These intracellular 
pathways can activate transcription factors such as c-fos, c-jun, c-myc, and egr-1, 
which in turn regulate many genes involved in cellular metabolism, myocardial 
growth and apoptosis [Sadoshima et al 1997]. The intracellular pathways are 
discussed below.  
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Ι.Ι.4.1. PI3K/Akt pathway 
PI3K/Akt plays an important role in the heart through regulation of cardiomyocyte 
growth, survival, function, and metabolism [Matsui et al 2003]. PI3K is activated 
by several receptor tyrosine kinases, such as the IGF-1 receptor and G protein-
coupled receptors. Study showed that PI3K is activated in pressure overload 
hypertrophy in a Gβγ-dependent fashion [Naga et al 2000]. Over-expression of a 
constitutively active PI3K mutant resulted in cardiac hypertrophy in transgenic 
mice [Shioi et al 2000]. Conversely, a dominant-negative form of PI3K led to 
significantly reduced heart weight/body weight ratios in transgenic mice. These 
changes indicate that PI3K in fact regulates the hypertrophic response. One of 
the principal targets of PI3K signaling is the serine/threonine kinase Akt, also 
known as protein kinase B (PKB). Akt is activated via binding of PI3K 
phosphorylated phosphoinositides, which in turn results in its translocation to the 
membrane. It has been shown that transgenic overexpression of Akt/PKB is 
sufficient to induce significant cardiac hypertrophy in mice [Shioi et al 2002, 
Matsui et al 2002]. Constitutive activation of Akt in skeletal muscle also causes 
hypertrophy [Bodine et al 2001].  
 
Ι.Ι.4.2. MAPKs pathway 
MAPKs play a significant role in hypertrophic signaling [Frey et al 2003]. This 
pathway provides an important link between external stimuli and the nucleus via 
phosphorylation and regulation of multiple transcription factors. MAPK 
superfamily is grouped into three categories including ERKs, JNKs, and p38 
MAPKs. ERKs have been reported to be responsible for the development of 
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hypertrophy [Glennon et al 1996]. Being a potent activator of AP-1 [Karin et al 
1996], the JNK/AP-1 cascade is considered to be involved in the increased 
expression of ANF, skeletal α-actin, TGF-β1, and collagen type I in cardiac 
hypertrophy [Kim et al 1999]. P38 MAPK has a potential role in cardiomyocyte 
hypertrophy in response to stress stimuli [Glennon et al 1996, Nemoto et al 1998, 
Wang et al 1998]. Among the p38 isoforms, the p38α and p38β are most 
important for hypertrophic responses [Molkentin et al 2001].  
 
Ι.Ι.4.3. PKC pathway 
PKC family consists of several serine/threonine kinases that are ubiquitously 
expressed and act downstream of almost all the membrane-associated signal 
transduction pathways [Nishizuka et al 1986]. Multiple studies implicate various 
PKC isoforms in the pathogenesis of cardiac hypertrophy. Transgenic 
overexpression of PKCβ in heart is sufficient to elicit cardiac hypertrophy and 
sudden death [Bowman et al 1997]. However, these findings were not confirmed 
in other studies [Huang et al 2001, Tian et al 1999]. In vivo, PKCε involvement 
has been shown in compensated cardiac hypertrophy [Takeishi et al 2000]. Study 
of Braz et al. [2002] showed that only PKCα is required to stimulate 
cardiomyocyte hypertrophy in vitro, further complicating the issue of the relative 
importance of PKC isoforms in this process.  
 
Ι.Ι.4.4. NF-κB pathway 
NF-κB is a redox-sensitive transcription factor and its signaling is critical in the 
development of atherosclerosis, myocarditis, ischemia, cardiac hypertrophy and 
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dilated cardiomyopathy [Jones et al 2003, Purcell et al 2003, Valen et al 2001]. 
Recent studies have suggested that the NF-κB activation plays an important role 
in the pathogenesis of cardiac remodeling and heart failure [Kalra et al 2000, 
Ritchie et al 1998, Wong et al 1998]. A major focus  is also directed toward NF-
κB contribution in cardiac hypertrophy, which is investigated in vitro [Gupta et al 
2002, Purcell et al 2001] and in vivo [Li et al 2004].  
 
Ι.Ι.5. Apoptosis 
Apoptotic nuclei are often observed in hypotrophic myofibers from patients with 
heart diseases. Apoptosis which contributes to the suppression of cardiac 
hypertrophy is the gene-regulated process of physiological cell self-destruction  
[Thompson 1995]. However, apoptosis has been shown to worsen  cardiac 
structure and plays a role in the transition of hypertrophic heart to heart failure 
[Nadal-Ginard et al 2003, Van Empel et al 2004]. Diez et al [1997] and Fortuno et 
al [1998]  reported that cardiomyocyte apoptosis is reduced after prolonged 
inhibition of the angiotensin pathway during the established phase of 
hypertension in the spontaneously hypertensive rats. Evidence suggests that two 
independent pathways may lead to cardiomyocyte apoptosis [Bishopric et al 
2001, Foo et al 2005]. The extrinsic (type I) pathway is initiated by ligands that 
bind to death receptors such as TNF receptor 1, whereas the intrinsic (type II) 
pathway is governed by the release of various proapoptotic proteins such as 
Cytochrome c (Cyt c), procaspases 2, 3, 9, and apoptosis-inducing factor (AIF) 
from the mitochondria. The inhibitors of apoptosis and cellular FLICE-like 
inhibitory protein prevent activation of the extrinsic pathway.  Bcl-2 is a major 
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regulator of mitochondrial membrane permeability and prevents activation of the 
intrinsic pathway. 
 
Ι.ΙΙ. Pulmonary hypertension (PH) and right ventricular hypertrophy 
Ι.ΙΙ.1. Modulation of cardiac makers in this pathology 
The most common causes of right ventricle hypertrophy (RVH) are RV outflow 
obstruction and PH. These changes damage the blood vessels in the lung, 
causing increased pressure in the remaining vessels. Natriuretic peptides are 
important markers of heart hypertrophy including RVH. However there are some 
differences in the biology of natriuretic peptides produced in the heart. ANP is 
mostly stored in granules in the atria, whereas BNP is released to blood as a 
result of ongoing synthesis in ventricular myocardium. ANP has shorter plasma 
half-time than BNP [Mukoyama et al 1991]. Nagaya et al [1998] found similar rate 
of elevation of both ANP and BNP in patients with volume overload, however, 
changes of ANP plasma levels were less evident than plasma BNP levels in 
response to RV pressure overload. Two studies [Nagaya et al 1998, Tulevski et 
al 2001] showed similar significant correlations of both plasma ANP and BNP 
with RV ejection fraction and similar correlations for both ANP and BNP in the 
plasma with haemodynamic variables. However, a head-to-head comparison of 
the two natriuretic peptides showed that changes of ANP plasma level were 
much less related to the effects of treatment and survival in patients with primary 
PH [Nagaya et al 2000], then BNP is why the interest regarding clinical 
application of natriuretic peptides in monitoring RV failure due to chronic PH 
focused on BNP. BNP synthesis and secretion are regulated at both gene and 
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protein levels.  At the protein level, proBNP, a high-molecular-weight precursor is 
synthesis at the final step. It is then cleaved into biologically inactive N-terminal 
segment (NT-proBNP) and the proper low-molecular-weight BNP [Wang et al 
2003].  Both BNP and NT-proBNP levels was useful in the diagnosis of left 
ventricular (LV) heart failure [Wensel et al 2002, McDonagh et al 2004, Doust et 
al 2005, Steg et al 2005, Jankowski, 2008]. NT-proBNP has longer half-life and 
better stability than BNP, both in the circulation and during storage. Studies 
[Fijalkowska et al 2006, Gan et al 2006] also found that the both BNP and NT-
proBNP plasma levels are related to the severity of right ventricular (RV) 
dysfunction, therefore, they could be considered as potential prognostic markers 
in this disease.  
 
Ι.ΙΙ.2. Investigations of RV and LV function following induction of PH with 
the monocrotaline  
Monocrotaline (MCT) is a toxic pyrrolizidine alkaloid isolated from the plant 
Crotalaria spectabilis and has been used extensively to produce PH in rats 
[Schultze et al 1998]. There have been numerous animal investigations of RV 
and LV function following induction of PH with the toxin MCT [Brunner et al 2002, 
Chen et al 1997, Chen et al 1997, Henriques-Coelho et al 2004, Wolkart et al 
2000]. A single dose of MCT in the rat results 7 weeks later in progressive and 
sustained PH [Meyrick et al 1980]. The pathological features such as pulmonary 
vasculitis, PH, and RVH seen following MCT administration are similar to those 
evident in human primary and secondary PH, which features are the thickening of 
the pulmonary arteries and narrowing of these blood vessels, as well as the 
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subsequent RVH. RV dysfunction in the setting of chronic PH has been well 
described both clinically and experimentally [Bonnet et al 2004, Kerbaul et al 
2004, Rich et al 2005]. In MCT-treated animals, there is evidence of elevated 
pulmonary vascular resistance, increased pulmonary artery pressure, and 
subsequent RVH [Meyrick et al 1980, Reindel et al 1990, Rosenberg et al 1988]. 
These changes are accompanied by increases in RV systolic and diastolic 
pressures and ultimately by RV failure [Brown et al 1998, Farahmand et al 2004, 
Honda et al 1992, Seyfarth et al 2000]. However, Akhavein et al [2007] showed 
that the impairment of cardiac function was associated with myocarditis and 
coronary arteriolar medial thickening and unrelated to the degree of PH, 
indicating a direct cardiotoxic effect of MCT.  
 
Ι.ΙΙΙ. Oxytocin (OT) and Oxytocin receptor (OTR) in the heart 
Ι.ΙΙΙ.1. General features of OT and OTR  
OT is a nine amino acid peptide structurally similar to closely related peptide 
arginine vasopressin, an antidiuretic hormone. OT is produced predominantly in 
magnocellular neurosecretory cells of the hypothalamus, transported to the 
posterior pituitary and secreted into the circulation. Although OT has an 
established role as a circulating hormone, it can also act as a “neurotransmitter 
and as a neuromodulator” by interacting with its central OTR within the brain 
[Gould et al 2003]. Circulating OT may originate from the brain or from peripheral 
tissues, because OT can also be synthesized in peripheral tissues such as 
corpus luteum, uterus, placenta, amnion, testis, pineal, thymus glands, mammary 
glands, kidney, heart, aorta and vena cava. OT is involved in female reproduction 
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where it is involved in the maintenance of parturition and the initiation of lactation 
[Blanks et al 2003]. OT is involved in male reproduction too. Metabolic activity of 
OT involves the triggering the insulin and glucagons secretions from the 
pancreas [Kolesnyk et al 2000]. Recent studies associated OT with increased 
glucose uptake by cardiac rat myocytes [Florian et al. 2009, Abstract QHA, 
Quebec City]. In adipocytes OT is also involved in insulin-like action [Hanif et al 
1982, Egan et al 1990]. The multiple hormonal and neurotransmitter functions of 
OT are mediated by the specific OTRs. There is only one OTR gene and 
therefore, the same receptor protein is expressed in brain and peripheral organs. 
The OTR is a typical class I G protein-coupled receptor that is primarily coupled 
via G(q) proteins to phospholipase C-beta. The high-affinity receptor state 
requires both Mg(2+) and cholesterol, which probably function as allosteric 
modulators [Gimpl et al 2001]. OTRs have also been demonstrated in many 
peripheral tissues, including the kidney, heart, thymus, pancreas, and adipocytes. 
Kimura et al [1992] first isolated and identified a cDNA encoding the human OTR 
using an expression cloning strategy. To date, the OTR encoding sequences 
from pig [Gorbulev et al 1993], rat [Rozen et al 1995], sheep [Riley et al 1995], 
bovine [Bathgate et al 1995], mouse [Kubuta et al 1996], and rhesus monkey 
[Salvatore et al 1998] have also been identified. 
 
Ι.ΙΙΙ.1.1. Cardiovascular functions of OT  
In rat heart, OT is expressed in atria at higher level than in ventricles. In vitro 
studies demonstrated that atrial myocytes secrete OT [Jankowski et al. 2000]. OT 
is reported to be a regulator of cell proliferation and a mediator for myoepithelial 
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cells differentiation in a mouse model [Reversi et al 2005]. OT exerts functions in 
the heart and vasculature by binding to OTR. The presence of OTR in the rat 
heart was demonstrated by autoradiography performed on frozen sections and 
the number of OT binding sites was similar in the atria and ventricles [Gutkowska 
et al 1997]. In the brain, the ANP and OT are co-localized in the same 
hypothalamic magnocellular neurons [Jirikowski et al 1986] with the highest 
percentage (90%) of oxytocinergic neurons containing ANP immunoreactivity 
found in the intersupraoptico-paraventricular island. The co-localization of both 
these peptides provides a morphological basis for their interaction in the 
modulation of physiological actions. Interaction between these hormonal system 
is also proposed in the heart. Experiments demonstrated physiologic function of 
OT in the mediation of ANP release from the heart [Gutkowska et al. 1997; 
Favaretto et al 1997]. An OT antagonist inhibited the stimulated and basal ANP 
release from perfused rat heart suggesting that the OT action in the heart is 
mediated by specific OTR [Gutkowska et al 1997]. OT is also able to modulate 
electrical and mechanical activities of atria, given that it promotes a reduction in 
both heart rate and force of atrial contraction, in concentrations that also 
stimulate ANP release [Gutkowska et al 1997, Mukaddam-Daher et al 2001, 
Favaretto et al 1997]. In addition, OT knockout mice show higher intrinsic heart 
rate, suggesting the existence of an intracardiac oxytocinergic system that 
modulates electrical activity of the heart [Michelini et al 2003]. Recent study has 
reported that the negative chronotropic action of oxytocin participates in its 
protective effects on ischemia-reperfusion-induced myocardial injury in a rat 
model [Ondrejcakova et al 2009].  
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Ι.ΙΙΙ.1.2. OT-ANP interaction in central nervous system  
OT released from the neural lobe may reach the heart by circulation to induce 
ANP release, but the intracardiac OT may also play a paracrine role in 
stimulating ANP release as mentioned above. On the other hand, endogenous 
hypothalamic ANP seems necessary to stimulate OT release in the 
hyperosmolality condition [Chirguer et al 2001]. The mature magnocellular 
neurons respond to perturbations in water balance by releasing large amounts of 
stored OT into the general circulation. This is accompanied by functional 
remodeling of the activity of the magnocellular neurosecretory neurons, the 
molecular basis of which is still unclear. 
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ΙΙ. HYPOTHESIS AND SPECIFIC AIMS 
ΙΙ.1. Hypothesis 
The hypothesis proposed in this thesis is that right ventricular hypertrophy 
induced in rat by pulmonary hypertension is related to the inflammation and 
changes of heart metabolism and these alterations inhibit local OTR expression. 
Therefore, impairment of OTR expression in right heart can be linked with local 
hypertrophy, and possibly, increased expression of cardioprotective hormones.       
This hypothesis is consistent with the recent findings suggesting OT role in heart 
metabolism (stimulation of glucose uptake in cardiomyocytes), cardiac cell growth 
(promotion of endothelial cell multiplication; differentiation of cardiac stem cells 
from the functional cardiomyocytes) and activation of genes involved in heart 
protection (natriuretic peptides and nitric oxide synthases).  
 
ΙΙ.2. Specific aims  
ΙΙ.2.1. Aim #1: To investigate gene and protein expressions of cardioprotective 
factors including OTR, NPs and NPRs and marker of pathological hypertrophy, 
Nab1 in RV and LV of MCT-treated and control rats.   
ΙΙ.2.2. Aim #2: To investigate gene and protein expressions of inflammatory 
markers including TNFα, IL-1β, and IL-6 and NOS in RV and LV of MCT-treated 
and control rats.   
ΙΙ.2.3. Aim #3: To investigate gene and protein expressions of metabolic factors 
including GLUT4 and IRAP in RV and LV of MCT-treated and control rats.   
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ΙΙΙ. EXPERIMENTAL DESIGN 
Male Sprague-Dawley rats with an initial body weight ranging from 220–250 
grams were used in this study. These rats were randomly divided into two 
groups: monocrotaline (MCT) - treated (n=7) or control (n=7). Since MCT was 
known to cause severe pulmonary hypertension in the rats, six to 7 weeks 
following the injection of MCT, rats were sacrificed. The hearts were extracted. 
The ratio of right ventricle to left ventricle plus septum weight (RV/LV + S) was 
used as an index of right ventricular hypertrophy. The tissues of right and left 
ventricles from MCT-treated and control rats were kindly provided by Dr. Tom 
Broderick and his colleague, Dr.Tiffany King. Total RNA and proteins were 
extracted from the tissues of right and left ventricles in the MCT treated and 
control rats. The gene expressions of oxytocin receptor (OTR), natriuretic 
peptides (NP) and its receptors (NPRs), nitric oxide synthases (NOS) including 
eNOS, iNOS, and nNOS, inflammatory cytokines including TNFalpha, IL-1beta, 
and IL-6, insulin regulated aminopeptidase (IRAP, oxytocinase), glucose 
transporter GLUT4, and marker of pathological hypertrophy, Nab1 were  
measured by real-time PCR. The protein expressions of OTR, TNFalpha, eNOS 
and iNOS, IRAP, GLUT4, and Nab1 were measured by Western-blot. Statistical 
evaluation of the results was done using Prism 3 software.     
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ΙV. MATERIAL AND METHODS 
ΙV.1. Animal treatment and collection of specimens  
Rats treated with MCT received a single injection at the concentration of 60 
mg/kg subcutaneously in the nape. MCT was dissolved in 0.5 N HCl and the pH 
was adjusted to 7.4 using 0.5 N of NaOH. Control rats received an equivalent 
amount of isotonic saline. Rats were placed two per cage and fed with standard 
rat food and water until sacrifice. The rats were kept in a temperature-controlled 
room with 12:12-h light-dark cycle. Six to seven weeks before animals were 
sacrificed and the heart was extracted, weighed and dissected into the left 
ventricle, right ventricle, and septum and then frozen with tongs cooled to the 
temperature of liquid nitrogen.  
 
ΙV.2. Measurement of gene expression 
ΙV.2.1. Table 1. Materials for Real-time PCR 
 
Reagents     Company  Cat No. 
 
Trizol      Invitrogen 15596-026 
Chloroform     Sigma  34854 
Isopropanol     Sigma  19516 
RNase-free Water    QIAGEN 129112 
DNase 1     Invitrogen 18047019 
RNaseOUT     Invitrogen 10777-019 
Random Primer             Invitrogen      48190-011   
M-MLV reverse transcriptase  Invitrogen 28025-013 
dNTP set (100mM each  A,C,G,T) Amersham 28-4065-51 
iQ™ SYBR® Green Supermix  BIO-RAD 170-8882 
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ΙV.2.2. Preparation of total RNA and quantification of RNA concentration 
ΙV.2.2.1. Preparation of total RNA 
Homogenize tissue samples in 1 ml of TRIZOL reagent per 50 to 100 mg of 
tissue. Add 0.2ml chloroforme per 1 ml of TRIZOL reagent. Shake samples 
vigorously for 15 seconds and incubate them at room temperature (RT) for 3 
minutes. Centrifuge samples for 15 minutes at 12000 x g at 4oC. Transfer the 
upper aqueous phase carefully without disturbing the interphase into a fresh 
tube. Add 0.5 (1 volume) isopropanol to precipitate RNA. Incubate samples for 10 
minutes at RT. Centrifuge samples for 10 minutes at 12000 x g at 4oC. Remove 
the supernatant completely. Wash the pellet with 1ml 75% ethanol and vortex 
samples for 1minutes. Centrifuge samples for 5 minutes at 7500 x g at 4oC. 
Remove all ethanol solution. Air-dry RNA pellet for 5 to 10minutes. Dissolve RNA 
in 19μl DEPC-treated water by passing solution a few times through a pipette tip.  
Incubate RNA solution for 5 minutes at 65oC.  
 
ΙV.2.2.2. Determination of RNA concentration  
Take 0.5ml DEPC water into new sterile test tubes. Vortex the RNA solutions 1 to 
2 seconds and spin them for 10 seconds. Pick up 2μl RNA and put into 0.5ml 
DEPC water. Determine the sample concentration and purity using UV/visible 
spectrophotometer to take OD at 260nm and 280 nm. The A
260
/A
280 
ratio should 
be above 1.6. Apply the convertion that 1 OD at 260 equals 40 μg /ml RNA. 
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ΙV.2.3. Reverse transcription of mRNA to cDNA 
Take 4ug RNA solution from each sample and complete them with DEPC H2O to 
the final volume 17 μl. Add 4ul Random Primer, vortex for 2 to 3 seconds and 
incubate these samples at 70oC for 10 minutes and then keep them on ice. Spin 
samples for 10 seconds and add 19ul master mix (8ul 5x buffer, 4ul DTT 0.1M, 
4ul dNTP 2.5mM, 1μl RNAseOut, 2ul MLV) to reach total volume of 40ul. Vortex 
above mixture of samples and master mix for 2 to 3 seconds and incubate them 
at 42oC for 60 minutes, and then followed incubation at 70oC for 5 minutes. 
Obtain cDNA and store them at -20oC.  
 
ΙV.2.4. Sequences of the primers used for PCR amplification of cDNA 
samples 
1) OTR:  
Forward primer: 5' CGTCAATGCGCCCAAGGAGA 3'  
Reverse primer: 5' ATGCAAACGAATAGACACCT 3' 
2) ANP: 
Forward primer: 5’ CAGCATGGGCTCCTTCTCCA 3’  
Reverse primer: 5’ GTCAATCCTACCCCCGAAGCAGCT 3’ 
3) BNP: 
Forward primer: 5’ CCATCGCAGCTGCCTGGCCCATCACTTCTG 3’  
Reverse primer: 5’ GACTGCGCCGATCCGGTC 3’  
4) GC-A: 
Forward primer : 5’ ATCACAGTGAATCACCAGGAGTTC 3’ 
Reverse primer : 5’AGATGTAGATAACTCTGCCCTTTCG 3’ 
 
5) GC-B:  
Forward primer: 5’ GCTACATGGTACCACCATATTTGGACAACCTC 3’  
 47
Reverse primer: 5’ CAGGAGTCCAGGAGGTCCTTTTCG 3’ 
6) NPR-C:  
 
Forward primer: 5’ ATCGTGCGCCACATCCCAGGCCAGT 3’  
Reverse primer: 5’ TCCAAAGTAATCACCAATAACCTCCTGGGTACCCGC3’ 
7) TNFalpha:  
Forward primer: 5’ CCCAGGGACCTCTCTCTAATCA 3’  
Reverse primer: 5’ GCTACAGGCTTGTCACTCGG 3’ 
 
8) IL-1beta:  
 
Forward primer: 5’ TCCCCAGCCCTTTTGTTGA 3’  
Reverse primer: 5’ TTAGAACCAAATGTGGCCGTG 3’ 
 
9) IL-6:  
 
Forward primer: 5’ TCTCCACAAGCGCCTTCG 3’  
Reverse primer: 5’ CTCAGGGCTGAGATGCCG 3’ 
 
10) eNOS: 
 
Forward primer: 5’ TACAGAGCAGCAAATCCAC 3’ 
Reverse primer: 5’ CAGGCTGCAGTCCTTTGATC 3’ 
 
11) iNOS:  
 
Forward primer: 5’ GATCAATAACCTGAAGCCCG 3’ 
Reverse primer: 5’ GCCCTTTTTTGCTCCATAGG 3’ 
 
12) nNOS:  
 
Forward primer: 5’ GGGCCATGTACCTGTCGTCCTC 3’ 
Reverse primer: 5’ TCCCTTTGTTGGTGGCATACTTGA 3’ 
 
 
13) GLUT4:  
 
Forward primer: 5’ ACCCTGGGCTCTGTATCCC 3’  
Reverse primer: 5’ CCCTGACCACTGAGTGCAAA 3’ 
 
14) IRAP: 
 
Forward primer: 5’ GTCTTGGTGAGCATGAGATGG 3’  
Reverse primer: 5’ CTAAGGTCCTGGCAGAGGGTA 3’ 
 
15) Nab1:  
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Forward primer: 5' TGCTGACAAGAAGAGATGAG 3' ’  
Reverse primer: 5’ TCCTGGTTTCCACAGACTAC 3'  
16) GAPDH:  
 
primer: 5’ TTCAATGGCACAGTCAAGGC 3’ 
Reverse primer: 5’ TCACCCCATTTGATGTTAGCC 3’ 
 
 
ΙV.2.5. Programs for amplification of gene sequences by Real-time PCR and 
control of amplification conditions 
Cycle 1:      95°C,  01’ 30’’ 
Cycle 2 (40x): 95°C,  00’ 25’’  
   60°C,  00’ 25’’’ 
   72°C,  00’ 40’’ 
Cycle 3:  95°C,  01’ 00’’ 
Cycle 4:  55°C,  01’ 00’’ 
Cylce 5 (40x):  55°C,  00’ 10’’ 
 
ΙV.2.6. Selection of housekeeping gene for measurement of gene 
expression semi quantitatively  
Housekeeping genes are used to normalize mRNA levels between samples for 
sensitive comparisons of mRNA transcription. A suitable housekeeping gene 
should be adequately expressed in the tissue of interest and shows minimal 
variability in expression between samples and under different experimental 
conditions. Commonly used housekeeping genes in real-time PCR include beta 
actin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ribosome small 
subunit (18S) ribsosomal RNA (rRNA), Ubiquitin C (UBC), hypoxanthine guanine 
phosphoribosyl transferase (HPRT), succinate dehydrogenase complex, subunit A 
(SDHA) and Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, theta polypeptide (YWHAQ). We choose GAPDH as housekeeping gene 
in our study for normalization, because this gene showed consistent expression 
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relative to other housekeeping genes among the treatment groups in our 
experiments.  
 
ΙV.2.7. Methodology used for calculation of the gene expression on the 
basis results provided by Real-time cycler 
Calculation of gene expression used the ∆∆CT method, which calculates relative 
expression with the equation: fold induction = 2–[∆∆CT]. The ∆∆CT method assumes 
that the amplification efficiencies of the target gene and the house-keeping gene 
are very similar. Data from the real-time cycler are displayed as amplification plots 
with fluorescence plotted against the number of cycles. The threshold as a broken 
line is either set manually by the user or automatically by the real-time cycler. It is 
the value where the fluorescence is above background, significantly below the 
plateau, and within the log-linear phase of the PCR. The threshold cycle (CT) is 
the cycle at which the amplification plot crosses the threshold. This is the cycle at 
which there is a significant detectable increase in fluorescence. A low CT value 
indicates high expression, as the template was detected after a low number of 
cycles. A high CT value indicates low expression, as the template was only 
detected after a high number of cycles. ∆∆CT= Ct gene of interest (unknown 
sample) – Ct GAPDH (unknown sample) – Ct gene of interest (calibrator sample) 
– Ct GAPDH (calibrator sample). One of the control samples, chosen as the 
calibrator sample, was employed in each PCR.  
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ΙV.2.8. Statistical evaluation of the results obtained by Real-time PCR 
Values are means ± SE of a minimum of five different animals. Statistical 
comparisons were made using Prism 3 software. Data were analyzed by two-way 
ANOVA. Comparisons between two groups were conducted by unpaired 
Student's t-test.  
 
ΙV.3. Cardiac protein extraction and Western blotting 
ΙV.3.1. Processing of cardiac samples and measurement of protein 
concentration 
ΙV.3.1.1. Processing of cardiac samples 
The heart was dissected into the left ventricle and right ventricle and then frozen 
with liquid nitrogen. Tissues were diced into small pieces, then transferred part of 
them into a big cylinder with 1 ml RIPA buffer containing the inhibitor of proteases 
(PMSF, EDTA and pepstatin; 10μl/ml). Samples were homogenized and 
incubated on a rotor at 4°C for 2h. Samples were then centrifuged at 12000 rpm 
for 20 minutes and supernatants were picked up into new tubes.  
 
ΙV.3.1.2. Measurement of protein concentration 
Prepare dye reagent by diluting 1 part Dye Reagent Concentrate with 4 parts 
distilled, deionized water. Prepare six dilutions of BSA standard.  Prepare test 
solution by mixing well 2ul samples with 98ul water in clean and dry glass test 
tubes. Protein solutions were assayed in duplicate. Add 2 ml of diluted dye 
reagent to each sample and standard solution tube and vortex. Incubate at room 
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temperature for at least 5 minutes. Transfer these solutions into cuvettes and 
measure absorbance at 595 nm.    
 
ΙV.3.2. Table 2. Reagents  for Western-blotting  
 
Reagents              Company   Cat No. 
 
PMSF     Sigma   P7626  
EDTA     Sigma   E6758   
Pepstatin     Sigma   P5318 
Glycine     Sigma   E6758    
Tris                                                Bio-Rad  161-0715  
SDS      Invitrogen  15525-017 
Beta-mercaptoethanol   Sigma   M7154   
Acrylamide     Invitrogen  15512-023  
N,N’-methylene-bis-acrylamide  Sigma   M7279 
NaCl      Sigma   S3014 
Methanol     Sigma   179337 
Acetic acid     Sigma   242853 
TEMED    Invitrogen  15524-010 
Ammonium persulfate   Sigma   A3678 
Tween 20     Sigma   P9416 
Protein standard for blotting  Bio-Rad  161-0374 
BSA      Sigma    B4287 
Skimmed milk   Milfresh   500g 
ECL detection reagents    Amersham   RPN2105 
Anti-OTR antibody   Santa Cruz    sc-8102                
Anti-TNFalpha antibody   Santa Cruz    sc-8301                
Anti-eNOS antibody   Santa Cruz    sc-654                      
Anti-iNOS antibody    Santa Cruz    sc-7271                  
Anti-Nab1 antibody    Santa Cruz    sc-12147       
Anti-IRAP antibody                        Alpha Diagnostic    IRAP11-S 
International 
Anti-GLUT4 antibody    Santa Cruz    sc-1608                  
Anti-GAPDH antibody    Santa Cruz    sc-25778                       
Anti-goat IgG-HRP antibody Santa Cruz    sc-2033 
Anti-rabbit IgG-HRP antibody  Santa Cruz    sc-2317 
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ΙV.3.3. Electrophoresis conditions, electro-transfer proteins to the nylon 
membrane 
10% acrylamide electrophoresis mini-vertical gel was prepared. This gel was set 
up in the tank which was filled up with 1X electrophoresis buffer. Samples were 
prepared with 5X SDS loading buffer, boiled for 3 minutes, and loaded into the 
wells of gel. The gel was run with 110-120V at 4oC until the line of  blue dye of 
samples reached the top of separating gel and then run with 170-180V until the 
line of blue dye of samples run out of the gel. The separating gel was cut out and 
put into the transfer solution for 15 minutes. Filter paper and a piece of nylon 
membrane were cut wider than the gel. The gel, filter paper, and nylon 
membrane were immersed in transfer solution and then protein transfer sandwich 
was made. Proteins in SDS are negatively-charged, so place sandwich form 
white side of transfer cassette as follows (flatten with each layer except for gel 
layer because gel is fragile): 1 piece pad, 3 pieces filter paper, nylon membrane, 
gel, 3 pieces filter paper, 1 piece pad. The transfer conditions were set at 20 to 
30V for overnight at 4oC.  
 
ΙV.3.4. Membrane processing, incubations time, reaction with specific 
primary antibodies, washing conditions, incubation with secondary 
antibodies 
After transfer of the protein to nylon membrane, the membrane was put in a box 
with Ponceau red for 3 minutes. Membrane was then rinsed with distilled water 
for 3 times and scanned. The membrane was washed 3 times with the buffer (1X 
TBS, 0.1% Tween 20, 10% milk) for 5, 10, and 15 minutes respectively which 
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was the washing conditions in our western-blot protocol. After washing, the 
membrane was incubated in the buffer (1X TBS, 0.1% Tween 20, 5% skimmed 
milk) for overnight at 4oC. After the membrane was blocked by milk, it was 
washed 3 times under the washing conditions.  The membrane then probed with 
specific primary antibodies for 1 to 3 days at 4°C. After washing again, the 
membrane was incubated with an appropriate peroxidase-conjugated secondary 
antibody according to the manufacturer's protocol. Detailed information of primary 
and secondary antibodies used in our study is listed at follows: 
 
Table 3. Primary and secondary antibodies used in Westen-Blot 
 
Primary antibodies  Concentrations  Secondary antibodies  Concentrations  
 
Anti-OTR               1:10000      Anti-goat IgG-HRP*            1:10000 
Anti-TNFalpha             1:2000            Anti-rabbit IgG-HRP          1:5000 
Anti-eNOS                    1:4000           Anti-rabbit IgG-HRP          1:10000   
Anti-iNOS                 1:400              Anti-rabbit IgG-HRP          1:5000 
Anti-Nab1       1:1000       Anti-goat IgG-HRP            1:10000 
Anti-IRAP                1:2000            Anti-rabbit IgG-HRP          1:5000 
Anti-GLUT4                   1:5000           Anti-goat IgG-HRP            1:10000 
Anti-GAPDH        1:20000           Anti-rabbit IgG-HRP          1:20000   
* HRP: Horseradish peroxidase, an enzyme commonly used as an indicator for 
chemical reactions produces peroxide which after reacting with appropriate 
substrates provides color or photolumininiscent effects. 
 
ΙV.3.5. Development of Western blotting reaction by chemiluminescence 
method  
Chemiluminescence method is that membrane-bound proteins are detected 
using specific protein-enzyme conjugates. The enzyme catalyzes 
chemiluminescence detection substrates to emit light, which produces an image 
on photosensitive film. Detailed procedures are as follows. Take the detection 
reagents substrates that are supplied from ECL kit and mix 2ml solution A and 
50ul solution B to obtain sufficient to cover the blots. Take out the blots from 
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washing buffer and remove the excessive washing buffer by placing the blots on 
paper towels. Transfer blots to a fresh container. Add mixed detection solution 
directly to the blots on the surface carrying the proteins. Incubate for precisely 5 
minutes at room temperature. Drain off excessive detection buffer and wrap blots 
in Saran Wrap. Place the blots in a film cassette. Switch off the light and place a 
sheet of Kodak X-Omat film on top of the blots, close the cassette, and expose 
for various times according to the sensitivity of target protein molecules. Develop 
films using developing equipment.   
 
ΙV.3.6. Molecular weight of the bands obtained for the studied protein of 
interest and expected molecular size as recommended by antibody 
provider and published in the literature  
 
Table 4. The size of Protein Bands  
 
Studied protein              Obtained MW kDa    Expected molecular size kDa      
 
        OTR       66     66    
     TNFalpha                   26     26 
        eNOS       140    140                    
        iNOS      130    130                  
        Nab1        65     54        
        IRAP                  150     150  
       GLUT4        45             40-45             
      GAPDH         37    35.8        
 
ΙV.3.7. Quantification of the bands intensity using computer software 
The Western blots were scanned and saved as “tif’’ files. The intensities of the 
bands were evaluated using the Adobe Photoshop 3.0 software. The procedures 
are as follows: Open the scanned image in Photoshop. Invert the image to let the 
dark parts of the film become light and the light parts become dark. On the first 
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band, use the lasso tool to draw a line all the way around the edges of the first 
band. This is where the judgement comes in to play, determining where the 
edges of the band are, and what is simply background. Check the values for the 
selection and record them to Excel.  
 
ΙV.3.8. Methodology used for calculation of protein expression in Western-
blot 
Calculation of protein expression in Western-blot was done using Microsoft Excel 
software. We used target protein values divided its GAPDH protein values to get 
ratios. The average value of these ratios of LVC (AV-R-LVC) was then 
calculated. Each ratio of target/GAPDH protein value in LVC, LVM, RVC, and 
RVM groups was divided by AV-R-LVC to have final percentage of protein 
expression in these groups.       
 
ΙV.3.9. Statistical evaluation of the results obtained by Western blotting 
Values are means ± SE of a minimum of five different animals. Statistical 
comparisons were made using Prism 3 software. Data were analyzed by one-way 
or two-way ANOVA. Comparisons between two groups were conducted by 
unpaired Student's t-test.  
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V. RESULTS 
V.1. Effect of MCT treatment on body weights and weights of selected 
organs  
Table 1 shows the effect of MCT treatment on selected organ weights. Rats 
injected with MCT had no significant differences in body weight, lung weight, and 
liver weight compared with the age-matched controls. Therefore, the ratios of the 
lung weight to body weight and the liver weight to body weight similar to the 
control rats was not affected by MCT-treatment. Table 2 shows the effect of MCT 
treatment on heart weight. As illustrated, the treatment of rats with MCT showed 
similar values in LV weight and septum weight compared with the controls. 
Consequently, in MCT-treated and control rats, the calculated ratio of LV weight 
to body weight displayed no change. In contrast, RV weight and total heart 
weight in MCT-treated rats markedly increased  and were significantly different  
compared to the control groups. As a result, the RV weight to LV + septum 
weight, the RV weight to body weight, and the total heart weight to body weight 
ratios were all significantly increased in the MCT-treated rats as compared to 
control rats. These results provided evidence of RV hypertrophy, because the 
ratio of the RV weight to the weight of LV plus septum and the ratio of the RV 
weight to body weight were nearly 77% and 131% higher in MCT-treated rats 
than that in control rats, respectively.     
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V.2. Effect of MCT treatment on NPs gene expressions in the right and the 
left ventricles  
The effect of MCT treatment on myocardial ANP and BNP gene expression in the 
LV and RV is illustrated in Figure 1. MCT treatment increased transcripts of ANP 
mRNA by 8-fold and BNP mRNA by 10-fold in RV (ANP gene expression in 
MCT-RV vs control: p=0.0004, BNP gene expression in MCT-RV vs. control: 
p=0.0003). At the lower extend, the MCT treatment increased transcripts of ANP 
mRNA  (3.7-fold) and BNP mRNA (2.7-fold) in LV (ANP gene expression MCT-
LV vs. control: p=0.03, BNP gene expression in MCT-LV vs control: p=0.0005). It 
has to be noted that LV expresses ANP and BNP mRNA at the higher level than 
RV both in control and MCT-treated groups (Statistical significance: ANP gene 
expression in control-LV vs. control-RV: p=0.0001, BNP gene expression in 
control-LV vs. control-RV: p=0.0001; ANP gene expression in MCT-LV vs. MCT-
RV: p=0.02, BNP gene expression in MCT-LV vs. MCT-RV: p=0.0001). The 
significant ANP and BNP mRNA increases in RV is consistent with elevation 
these transcripts in heart hypertrophy. However, in the MCT-LV, the ANP and 
BNP transcripts were elevated in the absence of the weight increase. Elevated 
ANP and BNP level in the LV can protect this chamber against hypertrophy.  
 
V.3. Effect of MCT treatment on NP receptors gene expressions in the right 
and the left ventricles  
As shown in Figure 2, MCT-induced specific hypertrophy in the RV was 
associated with increased gene expression of myocardial NP receptors. In the 
hypertrophied RV significantly increased the  transcripts of three NP receptors 
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and about 2 fold for GC-A, 1.5 fold for GC-B, and 2 fold for NPR-C (statistical 
significance were: GC-A gene expression in MCT-RV vs control: p=0.002; GC-B 
gene expression in MCT-RV vs control: p=0.02; NPR-C gene expression in MCT-
RV vs control: p=0.03). The changes in NP receptors mRNA were absent in the 
MCT-LV. This is specific effect in the right side of the heart or right ventricle.  
 
V.4. Effect of MCT treatment on NOS gene and protein expressions in the 
right and the left ventricles  
Figure 3 shows that in the LV of MCT-treated group, the eNOS was elevated 1.5-
fold both at the mRNA and protein levels. These results were significantly 
different compared with control group (eNOS gene expression in MCT-LV vs. 
control: p=0.03; eNOS protein expression in MCT-LV vs. control: p=0.0001). No 
changes of eNOS mRNA or proteins were found in the RV. In MCT-treated 
group, the level of eNOS protein in the LV was higher than that in RV (eNOS 
protein expression in MCT-LV vs MCT-RV: p=0.005) and in the control group, the 
level of eNOS protein in the LV was similar to that in RV. eNOS elevation in the 
LV can contribute in protection against hypertrophy.  
The iNOS protein expression in MCT-treated rats was significantly higher in 
enlarged RV compared with RV of control group (iNOS protein expression in 
MCT-RV vs. control:  p=0.0001). The effect of MCT treatment was not found at 
the level of iNOS mRNA expression. In addition, the iNOS protein levels were 
lower in the LV of MCT-treated than in the LV of control rats (iNOS protein 
expression in MCT-LV vs. control:  p=0.02).  However, in MCT-treated group, 
iNOS gene expression in LV was significantly higher than that in RV (iNOS gene 
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expression in MCT-LV vs MCT-RV: p=0.008). In contrast, iNOS protein 
expression in RV was greater than that in LV (iNOS protein expression in MCT-
RV vs MCT-LV: p=0.0001). These results show disagreement between   
transcript and protein levels of iNOS regarding MCT treatment as well as in 
relation to these measures in the ventricular chambers. Assuming that functional 
role is attributed to the iNOS protein, its elevation in the MCT-RV suggests local 
inflammation, as confirmed by pro-inflammatory cytokines.  
The nNOS transcripts were heightened 2 fold in the LV compared with control 
group (nNOS gene expression in MCT-LV vs control:  p=0.007), but no change 
were observed in RV. 
 
V.5. Effect of MCT treatment on OTR gene and protein expressions in the 
right and the left ventricles  
As shown in Figure 4, in RVH, both OTR mRNA and protein were decreased by 
~2-fold compared with corresponding OTR expressions in control groups (OTR 
gene expression in MCT-RV vs control: p=0.006, OTR protein expression in 
MCT-RV vs control: p=0.0005). In LV, OTR protein was about ~25% lower 
compared with control group (OTR protein in MCT-LV vs control: p=0.05), but no 
changes of OTR mRNA were detected. Interestingly, in control group, the OTR 
transcript in RV was significantly higher than that in LV (OTR gene expression in 
control-RV vs control-LV: p= 0.0001). This finding was in disagreement with the 
OTR protein levels observed in these heart chambers. As demonstrated in Figure 
4,  the level of OTR protein in LV was significantly higher than that in RV in MCT-
treated rats (OTR protein expression in MCT-LV vs MCT-RV: p= 0.0009). These 
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results suggest that post-transcriptional regulatory mechanisms of OTR 
processing can be different in RV and LV.            
 
V.6. Effect of MCT treatment on expressions of proinflammatory cytokines 
in the right and the left ventricles.  
Figure 5 shows that proinflammtory cytokines IL-1β and IL-6, but not TNFα were 
modulated by MCT treatment. Both IL-1β and IL-6 mRNAs increased 4-fold in 
hypertrophied RV compared to control RV (IL-1β gene expression in MCT-RV vs 
control: p=0.002, IL-6 gene expression in MCT-RV vs control: p=0.008), but no 
changes were found in LV. In MCT-treated rats, the levels of IL-1β and IL-6 
mRNA in the RV were markedly elevated comparing to the LV (IL-1β gene 
expression in MCT-RV vs MCT-LV: p=0.0003, IL-6 gene expression in MCT-RV 
vs MCT-LV: p=0.04). These findings suggest that MCT-induced inflammatory 
changes occur in RVH. We did not find any alterations in TNFα gene and protein 
in RV and LV in MCT-treated rats. More experiments for TNFα expression need 
to be conducted in order to reach a considerable conclusion.    
 
V.7. Effect of MCT treatment on a marker of pathological hypertrophy gene 
and protein expressions in the right and the left ventricles  
To further verify markers of pathological myocardial hypertrophy in MCT treated 
rats, the Nab1 gene expressions were tested in RV and LV and results were 
shown in Figure 6. In MCT-treated rats, the level of Nab 1 mRNA displayed two-
fold increase in RV hypertrophy compared to that of control group (Nab1 gene 
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expression in MCT-RV vs control: p=0.002), but not in LV. These results indicate 
the development of pathological right ventricle hypertrophy.  
 
V.8. Effect of MCT treatment on ventricular expression of factors involved 
in metabolic functions 
Figure 7 illustrates the gene and protein expressions of metabolic factors 
associated with cardiac OT system: the IRAP and GLUT4. IRAP gene expression 
significantly increased in RV hypertrophy compared to control RV (IRAP gene 
expression in MCT-RV vs control: p=0.004). In MCT-treated rats, the level of 
IRAP protein in RV was also significantly higher than that in LV (IRAP protein 
expression in MCT-RV vs MCT-LV: p=0.002). There were no significant 
differences between IRAP protein levels in MCT-treated group and control group 
both in the respect to RV and LV. GLUT4 protein content  in LV was significantly 
lower in MCT-treated rats as compared to LV of control group (GLUT4 protein 
expression in MCT-LV vs control: p=0.001), but no changes were observed in 
RV. There were no differences in the GLUT4 gene expression both in RV and LV 
between MCT-treated group and controls. However, in MCT-treated rats, the 
GLUT4 gene expression in the RV was significantly lower than in the LV (GLUT4 
gene expression in MCT-RV vs MCT-LV: p=0.02). In contrast, the GLUT4 protein 
in the RV was significantly higher than in LV (GLUT4 protein expression in MCT-
RV vs MCT-LV: p=0.03). Additional experiments should be performed to find 
correct conclusion for GLUT4 expression both at gene and protein level in MCT-
treated and control groups.  
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Table 1. Effect of monocrotaline treatment on selected organ weights. 
Values are means ± SEM for 7 control and 7 monocrotaline-treated rats.  
Values were determined 46 ± 1 day following a single dose injection  
of monocrotaline.  
Table 2. Effect of monocrotaline treatment on heart weight. 
Values are means ± SEM for 7 control and 7 monocrotaline-treated rats. 
Values  
were determined 46 ± 1 day following a single dose injection of monocrotaline.  
* P < 0.05 compared to control.  
Parameter Control Monocrotaline 
Body weight (g) 452 ± 10 436 ± 31 
Lung weight (g) 2.04 ± 0.21 2.05 ± 0.08 
Liver weight (g) 13.28 ± 0.06 13.27 ± 1.20 
Lung weight/body weight  
(x 10-3) 
4.51 ± 0.47 4.91 ± 0.55 
Liver weight/body weight 
(x 10-3) 
29.35 ± 1.25 30.20 ± 1.00 
Parameter Control Monocrotaline 
Heart weight (g) 1.13 ± 0.04 1.35 ± 0.07 * 
LV weight (g)  0.56 ± 0.04 0.51 ± 0.04 
RV weight (g) 0.20 ± 0.01 IRAP 
 
17 kDa Septum weight (g) 0.37 ± 0.02 0.40 ± 0.04  
RV/LV + septum weight (g) 0.74 ± 0.03 1.31 ± 0.15* 
 
RV/BW ratio (x10- 0.45 ± 0.01 1.04 ± 0.18 * 
LV/BW ratio (x10-3)  1.23 ± 0.07 1.20 ± 0.12 
HW/BW ratio (x10-3) 2.49 ± 0.08 3.15 ± 0.19 * 
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Figure 1. Effect of MCT on ANP and BNP gene expressions in the right and 
the left ventricle. Data illustrated on the graph bar represent the mean+SEM for 
7 hearts in each group. MCT vs control: *, P<0.05; **, P<0.001; RV vs LV: &, 
P<0.05; &&, P<0.001; &&&, P<0.0001.  
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Figure 2. Effect of MCT on NPR-A, NPR-B, and NPR-C gene expressions 
in the right and the left ventricle. Data illustrated on the graph bar represent 
the mean+SEM for 7 hearts in each group. MCT vs control: *, P<0.05; ***, 
P<0.0001.   
*** 
* 
* 
 65
 
 
 
 
 
LV RV 
0.0
0.5
1.0
1.5
2.0 Control
MCT
eN
O
S
 p
ro
te
in
 
LV RV 
0.0
1.0
2.0
0.5
1.5
Control
MCT
Control
MCT
LV RV
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
iN
O
S
 p
ro
te
in
LV RV
0.0
0.5
1.0
1.5
2.0
Control
MCT
LV RV
0 
1 
2 
3 
Control
MCT
nN
O
S
 m
R
N
A
Figure 3. Effect of MCT on eNOS and iNOS gene and protein expressions, and 
nNOS gene expression in the right and the left ventricle. Data illustrated on the 
graph bar represent the mean+SEM for 7 hearts in each group. MCT vs control: *, 
P<0.05; **, P<0.001; ***, P<0.0001. RV vs LV: &, P<0.05; &&, P<0.001.  
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Figure 4. Effect of MCT on OTR gene and protein expressions in the right and 
the left ventricle. Data illustrated on the graph bar represent the mean+SEM for 7 
hearts in each group. MCT vs control: *, P<0.05; **, P<0.001. RV vs LV: &&, 
P<0.001. 
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Figure 5. Effect of MCT on IL-1beta and IL-6 gene expressions, and TNFa gene 
and protein expressions in the right and the left ventricle. Data illustrated on 
the graph bar represent the mean+SEM for 7 hearts in each group. MCT vs control: 
*, P<0.05. LV vs RV: &, P<0.05; &&, P<0.001.  
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hearts in each group. MCT vs control: *, P<0.05.   
* 
36 kDa GAPDH 
Nab1 55 kDa 
N
ab
1 
m
R
N
A
 69
 
 
 
 
 
 
 
LV RV
0.00
0.25
0.50
0.75
1.00
1.25
Control
MCT
IR
A
P
 p
ro
te
in
 
LV RV
0.0
0.5
1.0
1.5 Control
MCT
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the right and the left ventricle. Data illustrated on the graph bar represent the 
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VΙ. DISCUSSION 
VΙ.1.  Rat model of RV hypertrophy 
Myocardial hypertrophy is a compensatory mechanism whereby cardiac tissue 
adapts to increased workload. Depending on the degree and duration of 
increased workload, ventricular hypertrophy may progress from a compensatory 
state to impaired systolic and/or diastolic function and heart failure. The model 
frequently used for studies of functional, structural and molecular changes due to 
RV compensated hypertrophy and RV failure, is animal treated with MCT. MCT 
selectively injures the endothelium of the lung vessels and induces pulmonary 
vasculitis. As a result develops muscularization and hypertrophy of media in 
pulmonary arteries thus increasing vascular resistance and stimulating local 
hypertension. Next, the PH leads to compensated RVH, which can progress to 
failure within weeks depending on the dose of MCT and the age of the animals. 
In the present study rats received a single dose (60 mg/kg) of MCT and the heart 
hypertrophy was investigated after 7 weeks. This protocol has been used 
extensively in experimental rats to cause PH and RVH [Broderick et al. 2008].  
Our data demonstrated that MCT-treated rats displayed significant increases in 
heart weight and RV weight. The presence of RVH induced by MCT was 
evidenced by an increase in the heart weight/body, RV/body weight, and 
RV/LV+S ratios. Indeed, the ratio of the RV weight to the weight of LV plus 
septum and the ratio of the RV weight to body weight were nearly 77% and 131% 
higher in MCT-treated rats than that in control rats, respectively. In contrast, MCT 
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treatment did not induce LV hypertrophy. These results are in accord with 
previous investigations [Miyauchi et al 1993, Honda et al. 1992, Brunner et al 
1999]. At molecular level, the RV hypertrophy was confirmed by elevated 
expression of hypertrophic markers such as ANP, BNP and Nab1 (NGF1A-
binding protein). Nab1, a member of a family of corepressors for early growth 
response (Egr) transcription factors, was found to interact with the inhibitory R1 
repression domain of Egr1, inhibiting its ability to activate transcription. Buitrago 
et al [2005] have described that Nab1 was an endogenous regulator of cardiac 
growth and increased in both mouse and human heart failure. They found that 
Nab1 is highly expressed in mammalian cardiac myocytes and inhibits cardiac 
myocyte hypertrophy through repression of Egr gene. Next, in vivo study  of 
transgenic mice with selective overexpression Nab1 gene in the heart identified 
that Nab1 is a potent inhibitor of heart hypertrophy stimulated by pathological 
stimuli. Indeed, they found that Nab1 overexpression suppressed hypertrophy 
induced by adrenergic activation and pressure overload, whereas excess of 
Nab1 not affected physiological heart growth during development and in 
response to exercise (Buitrago et al. 2005). These findings indicate the Nab1-
Egr1 axis acts as a selective regulator of heart growth in pathology. In the 
present study, the RVH induced by MCT was associated with the increased Nab1 
transcript in enlarged RV but not in the LV displaying the normal weight. This 
result was not confirmed by Western-blot. Because, the Nab1 protein is not 
available on the market, the verification of Nab1 antibody specificity by immune 
tests was not possible. Therefore, our results are only consistent in part with the 
suggestion that Nab1 can be used as a marker of pathological hypertrophy in the 
heart.  
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VΙ.2.  Possible role of inflammatory cytokines in the regulation of OTR 
OT exerts the functions in the heart and vasculature by binding to its receptor. 
OTR expression is regulated in multiple organs in a tissue- and development-
specific manner which may account for the distinct roles of OT in these tissues. 
The previous study demonstrated the presence of OTR in the mature rat heart by 
autoradiography performed on frozen sections [Gutkowska et al 1997]. The high 
OTR expression has observed during the rat early heart development [Jankowski 
et al. 2004]. Therefore, it is possible that high expression OTR in the RV can be 
associated with predominant circulatory function of RV in fetal life. OT 
administration reduces heart rate and force of contraction, and induces ANP 
release from heart which has been found both in vivo and in vitro studies 
[Haanwinckel et al 1995, Gutkowska et al 1997, Jankowski et al 1998]. Because 
most of these functions of OT were blocked by specific antagonist, it suggests 
that OTR play a key role in mediating OT cardiac functions. In the present study, 
we have demonstrated for the first time that OTR is down-regulated in RVH of 
MCT-treated rats. This was observed both on OTR mRNA and protein levels and 
by ~2-fold OTR lowering in RV of treated rats as compared to the RV of control 
rats. We found that in LV, only OTR protein expression, but not mRNA, was only 
slightly lower in MCT-treated rats compared to control rats (20%). The decrease 
of OTR in RVH may have functional significance in the hypertrophic heart and 
heart failure. The mechanisms involved in these changes are not clear. We 
hypothesize that decrease of OTR in RVH can cause decrease both of ANP and 
NO productions, which in turn induce cardiovascular diseases.  Indeed, Schmid 
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et al [2001]  demonstrated that the 5'-flanking region of the human OTR gene 
contains several putative binding sites for nuclear factor-IL6 (NF-IL6), also known 
as CAAT/enhancer binding protein-beta. This trans-acting factor modulates the 
expression of genes involved in acute inflammatory responses. In the present 
study have been shown that both IL-1β and IL-6 gene expression increased 
about 4-fold in RVH. Relevant to this finding is observation of Schmid et al [2001] 
who using deletion analysis and functional transfection studies in HeLa cells 
observed that both IL-1β and IL-6 treatment resulted in a significant decrease of 
OTR mRNA measured by ribonuclease protection assay. They reported that OTR 
gene promoter displays constitutive basal activity and is negatively regulated by 
both IL-1β and IL-6. This suppressive ability of IL-1β and IL-6 depends on the -
1203/-722 region of the OTR promoter, which contains binding sites for NF-IL6, 
acute phase response element, and NF-κB. Therefore, it is likely that the OTR 
expression is attenuated in the RV by inflammatory cytokines.  
Besides above investigations, accumulating evidence indicates that inflammatory 
cytokines play a pathogenic role in cardiac hypertrophy. In the patients, sustained 
increase in inflammatory cytokines, such as TNF , IL-1 and IL-6, contribute to 
cardiac remodeling and in the development of chronic heart failure [Deswal et al 
2001, Mann 2002, Malave et al 2003]. Animal studies have indicated that 
inflammatory cytokines induce cardiac hypertrophy [Li et al 2000]. IL-6 
significantly increased in rat model of cardiac hypertrophy due to pressure 
overload [Pan et al 1998]. Transgenic mice overexpressing IL-6 and IL-6 receptor 
developed hypertrophy of ventricular myocardium [Hirota et al 1995]. In MCT-
induced experimental models of PH, increased IL-6 mRNA expression was 
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associated with RVH [Bhargava et al 1999]. It has also been found that IL-1 was 
excessively produced in animals treated with MCT and the administration of an 
IL-1 receptor antagonist reduced PH and RVH [Voelkel et al 1994]. The 
observation from the present study showing increased IL-1β and IL-6 mRNA in 
the RV of MCT-treated rats is consistent with the above findings. It has been also 
reported that overexpression of TNF α in mice resulted in severe PH [Fujita et al 
2002]. This finding suggested that MCT-induced PH and its subsequent heart 
hypertrophy may also involve increased expression of TNFα. However, in 
present study, we did not find any changes in TNFα gene and protein 
expression. It is possible that TNFα contributes in the development cardiac 
hypertrophy in MCT model but its level is normalized when RVH is established. 
The time course studies are required to verify this hypothesis.   
 
VΙ.3.  Involvement of NO in RV hypertrophy 
As mentioned above, the evidence suggests the capability of IL-1β, IL-6, and 
TNFα to modulate myocardial functions. The literature indicates that pro-
inflammatory cytokines modulate myocardial functions through at least two 
different pathways. One is an immediate pathway that is manifested within 
minutes and involves activation of the neutral sphingomyelinase signaling [Oral et 
al 1997]. Second pathway, termed a delayed pathway, requires hours to days to 
develop and is mediated by NO [Gulick et al 1989, Baligand et al 1993]. Several 
studies have shown that treatment with IL1β leads to a depression in cardiac 
myocyte contractility, which is mediated by NOS [Combes et al 2002, Hosenpud 
1993, Schulz et al 1995]. NOS are NAPDH-requiring heme containing oxido-
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reductases that convert one of the chemically equivalent guanidino nitrogens of 
L-arginine to NO and the by product L-citrulline. In the heart, eNOS is expressed 
within the endothelium of the epicardial and microvascular coronary vessels and 
the endocardium, but also in cardiac myocytes and in cardiac pacemaker and 
conduction tissue, such as sinoatrial and atrioventricular nodal cells. In addition, 
the iNOS and nNOS are also present in cardiac myocytes. In the cultures cells, 
IL-1β was shown to induce myocyte growth and modulate cell morphology [Thaik 
et al 1995, Palmer et al 1995]. In their studies, they postulated that the signaling 
pathways for the effects of IL-1β may involve induction of iNOS gene in cardiac 
myocytes [Tsujino et al 1994] and NO independent mechanisms [Thaik et al 
1995, Palmer et al 1995].  In the study of Sasayama [1990], IL-6 enhanced de 
novo synthesis of iNOS protein, increased NO production and decreased rat 
cardiac myocyte contractility after 2h incubation. Activation iNOS in the heart is 
recognized as an inflammatory response (Anker and von Haehling. Inflammatory 
mediators in chronic heart failure: an overview. Heart.2004; 90: 464-470).  We 
have found that iNOS heightened in the RV of MCT-treated rats in parallel to IL-
1β and IL-6 mRNA increase. Based on these findings, it is possible that 
proinflammatory cytokines such as IL-1β and IL-6 modulate cardiac functions 
through iNOS-associated mechanism.  
 
VΙ.4.  Role of Natriuretic Peptides 
As mentioned in the introduction section, the natriuretic peptides contribute 
importantly to the maintenance of sodium and volume homeostasis in health and 
disease. Both ANP and BNP are synthesized predominantly by cardiac myocytes 
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and their production is increased by cardiac pressure and volume overload. In 
the present study, MCT-stimulated cardiac pressure or volume overload not 
changed LV mass. However the upregulation of the local ANP and BNP 
expression suggested that PH had an effect also on the gene expression in the 
LV. Correspondingly, we found that MCT treatment increased transcripts of ANP 
3.7-fold and BNP 2.7-fold in the LV compared to the control groups. Our findings 
not confirmed previous report of Usui et al. that after 8 weeks a single dose (60 
mg/kg) of MCT caused hypertrophy both in the RV and in the LV [2006]. On the 
other hand, they found that MCT treatment increased transcripts of ANP by 4-fold 
and BNP by 2-fold in the LV which is in agreement to our findings. In our study, 
the expression of natriuretic peptides mRNA in the LV was higher than in the RV. 
This difference was observed in the control rats and in MCT-treated rats. It can 
be speculated that the mechanisms by which MCT-treatment caused changes of 
both ANP and BNP mRNAs in non-hypertrophic LV may involve neurohumoral 
factors such as glucocorticoids, catecholamines, arginine vasopressin, 
angiotensin II, and endothelin [de Bold et al 2001]. This regulation may involve 
OT system, because several lines of evidence indicate a possible physiologic link 
of OT in ANP release from the heart [Gutkowska et al. 1997; Favaretto et al 
1997]. We found that MCT treatment increased transcripts of ANP with 8-fold and 
BNP with 10-fold in RV compared to the control groups. These results are 
consistent with the findings reported in the literature. Usui et al [2006] reported 
that MCT treatment increased transcripts of ANP by 3-fold and BNP by 5-fold in 
the RVH compared to the control groups. Chen et al [2001] has found that ANP 
gene expression increased about 4-fold in RVH of MCT-treated rats. The reason 
of increased expression of natriuretic peptides in the LV of rat with PH 
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hypertension is unknown. We can speculate that the increased synthesis of these 
peptides in LV is associated with stretch of ventricles and increased plasma ANP 
and BNP levels observed in MCT-treated rats [Usui et al 2006].   
The biological actions of natriuretic peptides are mediated by their specific 
receptors. Three NPR genes are expressed in ventricular tissues [Brown et al 
1993, Nunez et al 1992, Wilcox et al 1991] and transcripts for all three NPR 
subtypes have been found in ventricular cardiomyocytes [Lin et al 1995]. Deletion 
of GC-A in mice (GC-A –/–) prevents the vasorelaxant effects of ANP and BNP 
and leads to chronic hypertension and cardiac hypertrophy [Holtwick et al 2003]. 
In the present study, we found that transcripts for three NP receptors significantly 
increased about 0.3-2 fold only in the RV of MCT-treated rats compared to that of 
control groups. These findings suggest that increased gene expression of NP in 
the RV of the MCT-treated rat correlates with upregulation of NP receptor 
transcripts indicating local NP action in the RV during PH. 
 
VΙ.5.  Role of OT-Associated Metabolic Factors 
OT has metabolic activity to trigger the insulin and glucagons secretions from the 
pancreas [Kolesnyk et al 2000] and is associated with increased glucose uptake 
by cardiac rat myocytes [Florian et al. 2009, Abstract QHA, Quebec City]. OT 
also acts on adipocytes and displays a role in metabolic regulation related to 
feeding [Egan et al 1990]. Oxytocin mimics a number of insulin effects on 
adipocytes [Rodbell 1966, Rodbell 1964, Kanif et al 1982, Honeyman et al 1983]. 
However, in contrast to insulin, oxytocin stimulates phospholipid metabolism and 
diacylglycerol formation in adipocytes [Pennington et al 1985, Augert et al 1988]. 
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Moreover, exposure of isolated rat adipocytes to oxytocin increases PKC activity 
in adipocyte plasma membranes [Egan et al 1990]. The insulin-regulated 
membrane aminopeptidase (IRAP, oxytocinase) was originally identified in fat 
and muscle cells as a major protein in intracellular vesicles. IRAP colocalizes 
with the insulin-responsive glucose transporter GLUT4 in intracellular membrane 
vesicles. In cardiomyocytes, a fraction of intracellular GLUT4 has been found in 
large secretory granules that contain atrial natriuretic factor. IRAP has wide 
tissue distribution and is expressed by the heart. In IRAP-knockout mice and 
GLUT4-deficient mice develop cardiac hypertrophy. A recent study from 
Broderick et al [2008] has reported that MCT-induced RVH resulted in an 
increase in GLUT4 content in the right ventricle of the heart. This GLUT4 level 
increase in RV may potentially alter substrate energy metabolism. In present 
study, we found the IRAP gene expression significantly increased in RV 
hypertrophy compared to control RV and the level of IRAP protein in RV was 
significantly higher than that in LV in MCT-treated groups. However, the  GLUT4 
gene and protein expression obtained by RT-PCT and Western-blot analysis 
were not consistent with the recent findings from Broderick et al [2008]. This 
discrepancy requires explanation and additional experiments should be 
performed to find correct conclusion.  
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VII. CONCLUSIONS AND PERSPECTIVES 
VII.1. Conclusions 
Increased gene expression of NPs in the RV of the MCT-treated rat correlates 
with upregulation of NP receptor transcripts indicating local NP action in the RV 
during PH. OTR expression decreases in the RV possibly by inflammatory 
cytokines because OTR promoter region contains multiple putative interleukin-
response elements. This alteration possibly involves inflammatory NO-dependent 
mechanisms. Lowering OTR in RV during pulmonary hypertension can influence 
cardiac function since OT regulates heart rate and cardiac contractility.  
  
VII.2. Perspectives 
VII.2.1. OTR and inflammation  
Some of the molecular, and cellular events   implicated in the development of 
cardiac hypertrophy include cardiac myocyte-autonomous and 
endocrine/paracrine pathways [Molkentin et al 2001]. It has been suggested that 
the interaction between cardiac myocytes and surrounding non-myocytes, which 
consist mainly fibroblasts, is likely to be an important component of the 
hypertrophic process [Weber et al 1991]. This interaction might be mediated via a 
set of growth factors and cytokines, acting in an autocrine and/or paracrine 
fashions. Cytokines of the IL-6 family are of particular interest given recent 
reports of their ability to promote cross-talk between cardiomyocytes and 
fibroblasts [Mann 2003]. Some studies have demonstrated that oxytocin 
displayed antioxidant and anti-inflammatory effects [Detillion et al 2004, Iseri et al 
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2005a, Iseri et al 2005b, Petersson et al 2001]. It has been found that OTRs were 
expressed by several cells involved in inflammation, such as cultured human 
vascular endothelial cells [Thibonnier et al 1999], aortic smooth muscle cells 
[Yazawa et al 1996], and monocytes and macrophages [Szeto et al 2008]. The 
recruitment of macrophages into the myocardium has been identified in a model 
of cardiac hypertrophy [Behr et al 2004]. In the present study, we have 
demonstrated that OTR expression decreased both at the gene and protein 
levels in RVH and this alteration likely correlates with the increased inflammatory 
cytokines such as IL-1β and IL-6. However, the functional relevance of the 
downregulation of OTR in RVH remains unclear. To address this question, we 
propose to investigate the molecular mechanisms involved in OTR expression in 
RVH. The experiments should be performed in cultured cardiac myocytes, 
cultured cardiac fibroblasts, and cultured macrophages, and their co-cultures. In 
cardiac myocytes the changes of OTR expression, cell morphology and ANP 
accumulation should be investigated. These parameters will be examined in 
response to added cytokines or to conditioned media collected from fibroblast 
and macrophages growing in the presence and the absence of OT.  The addition 
of OT and cytokines receptor antagonists will confirm specificity of results 
obtained in the experiments. These studies will provide information whether 
cross-talks between cardiac myocytes and cells activated during heart 
inflammation involves OT mediation.  
 
VII.2.2. OTR and metabolism  
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In the present study, we found that IRAP expression significantly increased in RV 
hypertrophy induced in rats by MCT treatment. The interaction between OTR and 
IRAP in RVH has not been studied yet. IRAP is recently found as a signal 
transducing receptor of angiotensin IV and as a member of the family of zinc-
dependent membrane aminopeptidases. The members of this family have been 
shown to process regulatory peptides, thereby changing their activities [Barrett et 
al 1998]. It is important to note that the physiological roles of aminopeptidases A 
and N in the cleavage and regulation of the actions of angiotensin II and 
angiotensin III, respectively, have been established [Reaux et al 2000]. It has 
been documented in ex vivo studies that IRAP cleaves several peptide hormones 
including OT and AVP [Tsujimoto et al 1992, Herbst et al 1997, Matsumoto et al 
2001]. IRAP cleaves OT and thus prevents OTR activation. OT is known to mimic 
many of the effects of insulin in adipocytes, stimulating glucose oxidation, 
lipogenesis, and glycogen synthesis. These insulin-like activities are due to OT 
binding to the OTR and not to the insulin receptor itself [Hanif et al 1982]. We 
have presently found that OTR receptor was down-regulated in RVH of MCT-
treated rats. On the other hand, it is possible that increased IRAP in RVH 
degrades OT and further attenuates OTR signal transduction. Therefore, we 
propose to investigate functional interaction between IRAP and OT/OTR in 
cultured cardiac myocytes and also to study the molecular mechanisms involved.  
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